[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20190192655A1 - Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy - Google Patents

Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy Download PDF

Info

Publication number
US20190192655A1
US20190192655A1 US16/121,867 US201816121867A US2019192655A1 US 20190192655 A1 US20190192655 A1 US 20190192655A1 US 201816121867 A US201816121867 A US 201816121867A US 2019192655 A1 US2019192655 A1 US 2019192655A1
Authority
US
United States
Prior art keywords
radiation therapy
administered
antibody
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/121,867
Inventor
Ross A. Stewart
Michelle Morrow
Robert W. Wilkinson
Edmund Poon
Simon Dovedi
Tim Illidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53498965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20190192655(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to US16/121,867 priority Critical patent/US20190192655A1/en
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEWART, ROSS A., WILKINSON, ROBERT W., POON, Edmund, MORROW, MICHELLE
Assigned to THE UNIVERSITY OF MANCHESTER reassignment THE UNIVERSITY OF MANCHESTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOVEDI, Simon
Assigned to THE UNIVERSITY OF MANCHESTER reassignment THE UNIVERSITY OF MANCHESTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ILLIDGE, Tim
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE UNIVERSITY OF MANCHESTER
Publication of US20190192655A1 publication Critical patent/US20190192655A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • RT Radiation therapy
  • RT can lead to expression of ecto-calreticulin on tumor cells as well as the release of several damage-associated molecular patterns (DAMPs) including High Mobility Group Box 1 (HMGB1) and ATP which can lead to recruitment and activation of antigen presenting cells (APCs) and priming of tumor antigen-specific T cell responses (6-10).
  • DAMPs damage-associated molecular patterns
  • APCs antigen presenting cells
  • the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is involved in the maintenance of peripheral tolerance and the modulation of acute inflammatory responses through inhibition of T cell function and through apoptosis of activated T cells (12, 13).
  • PD-L1 can also suppress T cell function through interaction with CD80 (14).
  • Expression of PD-L1 is inducible and thought to respond to local inflammatory milieu, particularly type I and II interferon (IFN) (12, 15, 16). Although barely detectable in most normal tissues, expression of PD-L1 has been described in multiple malignancies (reviewed in (17)).
  • IFN interferon
  • a dosing strategy for combining radiation therapy and a PD-1 and/or PD-L1antagonist is desired to create maximal benefit for patients suffering from cancer.
  • a method of treating cancer in a patient comprises
  • the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof.
  • the radiation therapy is fractionated radiation therapy.
  • the fractionated radiation therapy comprises from 2 to 7 fractions. In another mode, the fractionated radiation therapy comprises 5 fractions.
  • the radiation therapy fractions are administered in sequential days. In another embodiment, the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5. In one embodiment, the radiation therapy comprises about 10 Gy in 5 fractions.
  • the at least one PD-1 and/or PD-L1 antagonist is administered on at least day 1 and/or on day 5.
  • the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
  • the at least one PD-1 and/or PD-L1 antagonist may be administered 3 times a week.
  • the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
  • the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • the cancer is melanoma, colorectal cancer, or breast cancer.
  • more than one treatment cycle is performed.
  • from 2-8 treatment cycles are performed.
  • treatment cycles are weekly or every other week.
  • FIGS. 1A-1F illustrate that blockade of the PD-1/PD-L1 axis potentiates the activity of fractionated radiation therapy.
  • a and B median fluorescence intensity ( FIG. 1A ) and representative histograms ( FIG. 1B ) of PD-L1 expression on CT26 cells isolated from tumors 1, 3 or 7 days after treatment with about 10 Gy in 5 daily fractions of 2 Gy.
  • C and D CT26 tumor bearing mice received about 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with either ⁇ PD-1 ( FIG. 1C ) or ⁇ PD-L1 ( FIG. 1D ) mAb dosed at 10 mg/kg 3qw for up to 3 weeks.
  • FIG. 1C median fluorescence intensity
  • FIG. 1B representative histograms of PD-L1 expression on CT26 cells isolated from tumors 1, 3 or 7 days after treatment with about 10 Gy in 5 daily fractions of 2 Gy.
  • C and D CT26 tumor bearing mice received about 10 Gy RT delivered in 5
  • FIG. 1E tumor volumes 10 days after the start of therapy in 4T1 tumor bearing mice that received 20 Gy RT delivered in 5 daily fractions of 4 Gy either alone or in combination with ⁇ PD-L1 mAb.
  • FIG. 1F 4434 tumor bearing mice received about 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with ⁇ PD-L1 mAb.
  • Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments.
  • A, E and F show mean ⁇ SEM. *, P ⁇ 0.05 **, P ⁇ 0.01, Mann-Whitney test.
  • FIGS. 1C and 1D *, denotes significance when compared to control mice. + , denotes significance when compared to monotherapy. *** /+++ , P ⁇ 0.001, Log-rank (Mantel-Cox) test.
  • FIGS. 2A-2C demonstrate that therapeutic activity of fractionated RT and ⁇ PD-L1 mAb combination is dependent on the activity of CD8+ T-lymphocytes.
  • FIG. 2A tumor volume on day of therapy, 7 and 11 days post combination therapy with 5 fractions of 2 Gy and ⁇ PD-L1 mAb.
  • Immune cell subsets (either CD8, CD4 or NK cell) were depleted 1 day prior to therapy with depletion maintained for 2 weeks. ***, P>0.001, *, P>0.01, *, P>0.05, Mann-Whitney test.
  • FIG. 2B Survival curve. *** /+++ , P ⁇ 0.001, Log-rank (Mantel-Cox) test. Data representative of 10 mice per cohort.
  • FIG. 2C representative density plots of peripheral blood confirming depletion of immune cell subsets.
  • FIGS. 3A-3C show that fractionated RT and ⁇ PD-L1 mAb combination generates protective immunological memory.
  • FIG. 3A Survival curve of LTS mice following contralateral rechallenge with 5 ⁇ 10 5 CT26 cells. * P ⁇ 0.05 compared to control mice (log-rank; Mantel-Cox test).
  • FIG. 3B representative dot blot of IFN ⁇ production by CD8 + T cells isolated from either tumor na ⁇ ve, or LTS mice originally treated with RT and ⁇ PD-L1 mAb.
  • FIG. 3A Survival curve of LTS mice following contralateral rechallenge with 5 ⁇ 10 5 CT26 cells. * P ⁇ 0.05 compared to control mice (log-rank; Mantel-Cox test).
  • FIG. 3B representative dot blot of IFN ⁇ production by CD8 + T cells isolated from either tumor na ⁇ ve, or LTS mice originally treated with RT and ⁇ PD-L1 mAb.
  • FIGS. 4A-4C illustrate that fractionated RT increases tumor cell PD-L1 expression in vivo and is dependent on CD8 + T cells.
  • FIG. 4A Expression of PD-L1 on CT26 cells post treatment with RT (2.5-10Gy) in vitro.
  • FIGS. 4B and 4C Representative contour plots ( FIG. 4B ) and median fluorescence intensity ( FIG. 4C ) of PD-L1 expression on CT26 cells (gated as CD45 ⁇ cells) isolated from tumors 3 days after receiving about 10 Gy in 5 daily fractions of 2Gy in combination with either CD8, CD4 or NK cell depleting antibodies. * P ⁇ 0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at least 2 independent experiments.
  • FIGS. 5A-5E show that CD8 + T cell production of IFN ⁇ is responsible for the upregulation of PD-L1 expression on tumor cells following fractionated RT.
  • FIG. 5A Expression of PD-L1 on wild-type CT26 tumor cells (WT), or cells transduced with either a non-targeting control (NTC) or IFN ⁇ R1 ShRNA following co-culture for 24 hours with either 20 ng/ml IFN ⁇ , TNF ⁇ or a combination of both cytokines.
  • FIG. 5B representative density plots showing expression of IFN ⁇ and TNF ⁇ by CD8 + T cells following treatment with either PBS or phorbol 12-myristate 13-acetate (PMA) and ionomycin, FIG.
  • PMA phorbol 12-myristate 13-acetate
  • FIGS. 5D and 5E representative contour plots ( FIG. 5D ) and median fluorescence intensity ( FIG. 5E ) of PD-L1 expression on CT26 tumor cells following treatment with RT (about 10 Gy in 5 fractions) in the presence of an ⁇ IFN ⁇ blocking mAb (or isotype control) in vivo. ** P ⁇ 0.01, (Mann-Whitney test).
  • Experimental groups contained at least 5 mice.
  • FIGS. 6A-6D demonstrate that dosing schedule impacts outcomes with RT potentiation only observed with concurrent but not sequential ⁇ PD-L1 mAb therapy.
  • FIG. 6A Schema for dose-scheduling studies. Mice received fractionated dose RT (as about 10 Gy in 5 daily fractions of 2 Gy) alone or in combination with ⁇ PD-L1 mAb starting either on day 1 of RT cycle (schedule A), day 5 of RT cycle (schedule B) or 7 days post the last dose of RT (Schedule C).
  • FIG. 6B Survival curves of therapy. ++ , P ⁇ 0.01 compared to monotherapy (log-rank; Mantel-Cox test).
  • FIGS. 6A-6D demonstrate that dosing schedule impacts outcomes with RT potentiation only observed with concurrent but not sequential ⁇ PD-L1 mAb therapy.
  • FIG. 6A Schema for dose-scheduling studies. Mice received fractionated dose RT (as about 10 Gy in 5
  • FIG. 6C and 6D Expression of PD-1 on CD4 + ( FIG. 6C ) and CD8 + ( FIG. 6D ) T cells 24 hours and 7 days after the last dose of RT. * P ⁇ 0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at least 2 independent experiments.
  • FIG. 7 shows blockade of both PD-1 and PD-L1 does not further enhance efficacy in combination with fractionated RT in CT26-tumor bearing mice.
  • Experimental groups contained at least 5 mice and are representative of at 2 independent experiments.
  • FIGS. 8A-8B show combination therapy with fractionated RT and either ⁇ PD-1 or ⁇ PD-L1 mAb is well tolerated in mice.
  • CT26 tumor bearing mice received 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with ⁇ PD-L1 mAb dosed at 10 mg/kg 3qw either for 3 weeks or 1 week.
  • Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments. n/s, P>0.05, Mann-Whitney test.
  • FIGS. 9A-9C illustrate that treatment of tumor cells with ⁇ PD-1 or ⁇ PD-L1 mAb does not sensitise to radiation-induced cell death in vitro.
  • FIGS. 10A-10C show that the dosing schedule impacts outcome.
  • FIG. 10A tumour volumes following fractionated dose RT (as 10 Gy in 5 daily fractions of 2 Gy) alone or in combination with ⁇ PD-L1 mAb starting either on day 1 of RT cycle (schedule A), day 5 of RT cycle (schedule B) or 7 days post the last dose of RT (Schedule C).
  • FIGS. 10B and 10C tumour volumes of RT-treated mice demonstrating equivalent tumor volumes across different dosing schedules. n/s, P>0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at 2 independent experiments.
  • FIG. 11 shows that acute versus chronic administration of ⁇ PD-L1 mAb does not impact efficacy of combination therapy.
  • CT26 tumor bearing mice received 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with ⁇ PD-L1 mAb dosed at 10 mg/kg 3qw either for 3 weeks or 1 week.
  • Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments. n/s, P>0.05, log-rank; Mantel-Cox test.
  • Table 1 provides a listing of certain sequences referenced in present embodiments. CDRs have been indicated in bold and underlining.
  • the present methods encompass treatment of cancer employing at least one dose or radiation therapy and at least one dose of at least one PD-1 and/or PD-L1 antagonist.
  • a method of treating cancer in a patient may include administering at least one dose of radiation therapy and administering at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
  • the method of treating cancer may be administered once (as a single treatment cycle) or it may be administered more than once (i.e., with multiple treatment cycles), such as on a weekly, every other week, every three weeks, or every month cycle. If the method is administered more than once, it may be administered 2, 3, 4, 5, 6, 7, or 8 times, or more.
  • fractionated RT delivered in combination with ⁇ PD-1 or ⁇ PD-L1 mAbs generated effective anti-tumor CD8 + responses, which improved local tumor control and long-term survival, and protected against tumor rechallenge by the induction of a tumor antigen-specific memory immune response.
  • CD8 + T cell production of IFN ⁇ was found to be responsible for the upregulation of PD-L1 on tumor cells following fractionated RT.
  • the at least one PD-1 and/or PD-L1 antagonist for use the present methods is an anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof.
  • the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
  • the at least one PD-1 and/or PD-L1 antagonist may also be administered on day 1 of the treatment cycle (i.e., the same day as a dose of radiation therapy).
  • the at least one PD-1 and/or PD-L1 antagonist is administered on day 5 (i.e., 4 days later).
  • the PD-1 and/or PD-L1 antagonist may be administered on day 1, day 2, day 3, day 4, day 5, day 6, and/or day 7 of a treatment cycle (including both single and multiple treatment schedules).
  • the at least one PD-1 and/or PD-L1 antagonist is administered multiple times in a treatment cycle. In another embodiment, the at least one PD-1 and/or PD-L1 antagonist is administered 2, 3, 4, 5 or more times in a treatment cycle. For example, the antagonist may be administered three times a week for a one-week treatment cycle, or three times a week for a treatment cycle with two or more weeks as described above.
  • the antibody or functional part thereof is chosen from those disclosed in US Publication 2010/0028330, which is incorporated by reference for the teaching of these antibodies and functional parts thereof. In one embodiment, the antibody if MEDI4736.
  • the anti-PD-1 and/or anti-PD-L1 antibody is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • the antibodies or functional parts thereof are administered in therapeutically effective amounts.
  • a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition of the subject.
  • a therapeutically effective amount of an antibody or functional part thereof ranges from about 0.001 to about 30 mg/kg body weight, from about 0.01 to about 25 mg/kg body weight, from about 0.1 to about 20 mg/kg body weight, or from about 1 to about 10 mg/kg.
  • the dosage may be adjusted, as necessary, to suit observed effects of the treatment. The appropriate dose is chosen based on clinical indications by a treating physician.
  • the antibodies may be given as a bolus dose, to maximize the circulating levels of antibodies for the greatest length of time after the dose. Continuous infusion may also be used after the bolus dose.
  • the term antibody or functional part thereof is used in the broadest sense. It may be man-made such as monoclonal antibodies (mAbs) produced by conventional hybridoma technology, recombinant technology and/or a functional fragment thereof. It may include both intact immunoglobulin molecules for example a polyclonal antibody, a monoclonal antibody (mAb), a monospecific antibody, a bispecific antibody, a polyspecific antibody, a human antibody, a humanized antibody, an animal antibody (e.g.
  • the functional part is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab′) 2 fragment.
  • an antibody or functional part is said to be “capable of binding” a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody.
  • Antibody fragments or portions may lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody.
  • Examples of antibody may be produced from intact antibodies using methods well known in the art, for example by proteolytic cleavage with enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′) 2 fragments).
  • Portions of antibodies may be made by any of the above methods, or may be made by expressing a portion of the recombinant molecule.
  • the CDR region(s) of a recombinant antibody may be isolated and subcloned into an appropriate expression vector.
  • an antibody or functional part is a human antibody.
  • the use of human antibodies for human therapy may diminish the chance of side effects due to an immunological reaction in a human individual against nonhuman sequences.
  • the antibody or functional part is humanized.
  • an antibody or functional part is a chimeric antibody. This way, sequences of interest, such as for instance a binding site of interest, can be included into an antibody or functional part.
  • the antibody may have an IgG, IgA, IgM, or IgE isotype. In one embodiment, the antibody is an IgG.
  • Radiation therapy also known as high-dose ionizing irradiation, is a component of the present therapeutic approach.
  • the radiation therapy is fractionated radiation therapy.
  • the fractionated radiation therapy comprises from 2 to 7 fractions.
  • the fractionated radiation therapy comprises from 3 to 6 fractions.
  • the fractionated radiation therapy comprises from 4 to 5 fractions.
  • the fractionated radiation therapy comprises 2, 3, 4, 5, 6, or 7 fractions. In one embodiment, the fractionated radiation therapy comprises 5 fractions.
  • the radiation therapy fractions are administered in sequential days.
  • radiation therapy may include more than one dose on a day and/or doses on sequential days.
  • the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5.
  • the radiation therapy comprises about 10 Gy in 5 fractions (i.e., 2 Gy on each of 5 days).
  • fractionation schedules may be employed including accelerated fractionation (treatment given in larger daily or weekly doses to reduce the number of weeks of treatment), hyperfractionation (smaller doses of radiation given more than once a day), or hypofractionation (larger doses given once a day or less often to reduce the number of treatments).
  • the radiation therapy may be x-rays, gamma rays, or charged particles.
  • the radiation therapy may be external-beam radiation therapy or internal radiation therapy (also called brachytherapy).
  • Systemic radiation therapy, using radioactive substances, such as radioactive iodine, may also be employed.
  • External-beam radiation therapy includes 3D conformational radiation therapy, intensity-modulated radiation therapy, image-guided radiation therapy, tomotherapy, stereotactic radiosurgery, proton therapy, or other charged particle beams.
  • the present methods may be used to treat a variety of types of cancer.
  • the method may be used to treat melanoma, colorectal cancer, or breast cancer.
  • the breast cancer is triple negative breast cancer.
  • the cancer is cancer is adrenocortical tumors, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, chest cancer, colon cancer, colorectal cancer, endometrial cancer, epidermoid carcinoma, esophageal cancer, eye cancer, glioblastoma, glioma, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor, gestational trophoblastic disease, head and neck, Hodgkin disease, Kaposi sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, leukemia, liver cancer (such as hepatocellular carcinoma), lung cancer (including non-small cell, small cell, and lung carcinoid tumors), lymph node cancer, lymphoma, lymphoma of the skin, melanoma, mesothelioma, mouth cancer, multiple myeloma, nasal cavity and par
  • BALB/c and C57Bl/6 mice were obtained from Harlan, U.K. All animal experiments were approved by a local ethical committee and performed under a United Kingdom Home Office license.
  • CT26 murine colon carcinoma cells (ATCC) and 4434 cells isolated from BRafV600E p16 ⁇ / ⁇ mice were maintained in DMEM, and 4T1 triple negative breast cancers (ATCC) maintained in RPMI-1640, supplemented with 10% FCS, 1% L-glutamine (Invitrogen, U.K.). All cell lines were routinely screened to confirm the absence of Mycoplasma contamination.
  • mice were inoculated sub-cutaneously (s.c.) with either 5 ⁇ 10 5 CT26, 1 ⁇ 10 5 4T1 or 5 ⁇ 10 6 4434 cells. Irradiations were performed 7-10 days after inoculation (when tumors were at least 100 mm 3 ) using a Pantak HF-320 320 kV x-ray unit (Gulmay Medical, U.K.). The machine was operated at 300 kV, 9.2 mA, with filtration fitted in the x-ray beam to give a radiation quality of 2.3 mm Cu half-value layer. Mice were positioned at a distance of 350 mm from the x-ray focus, where the dose rate was 0.80 Gy/min.
  • mice received either ⁇ CD8 mAb; clone YTS169 (a gift from M.
  • mice were implanted contralaterally with tumor cells a minimum of 100 days after previous tumor implantation. Additional control mice were also implanted to confirm tumor growth.
  • Experimental groups contained at least 5 mice/group and are representative at least 2 independent experiments.
  • splenocytes from either LTS or control mice were cultured for 5 days in RPMI-1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 1% L-glutamine, 50 ⁇ M 2-ME and 10 IU/ml human recombinant IL-2 in the presence of either 1 ⁇ 10 6 tumor cells irradiated with 50 Gy or 1 ⁇ mol/ml of the H2-Ld restricted peptides SPSYVYHQF (SEQ ID NO: 91) (AH1)/TPHPARIGL (SEQ ID NO: 92) ( ⁇ -galactosidase) (Anaspec, U.K.).
  • mice were restimulated at a 1:1 ratio with 50 Gy irradiated tumor cells for 16 hours in the presence of 3 ug/ml Brefeldin A (BD Pharmingen, U.K.) and 100 IU/ml human recombinant IL-2 (Chiron, NL).
  • Brefeldin A BD Pharmingen, U.K.
  • human recombinant IL-2 Choiron, NL
  • FACS analysis cells were washed and incubated with rat anti-CD16/32 (eBioscience, U.K.) to block non-specific binding and then stained with a FITC conjugated anti-CD8 ⁇ mAb (eBioscience, U.K.). Cells were then fixed/permeabilized and stained for expression of IFN ⁇ using an APC conjugated mAb (eBioscience, U.K.).
  • tumors were processed using a gentleMacs dissociator and a murine tumor dissociation kit (Miltenyi Biotec, U.K.). For analysis, non-specific binding was blocked as described above and expression of CD4, CD8 (BD Biosciences, UK), CD45, NKP46, PD-1 and PD-L1 examined by multi-parameter flow cytometry (all eBioscience unless otherwise stated).
  • Tumor cells were cultured in the presence of 20 ng/ml IFN ⁇ and/or TNF ⁇ for 24 hours prior to evaluation of PD-L1 expression by flow cytometry as described above.
  • For co-culture assay either resting or activated splenocytes (treated with PBS or phorbol 12-Myristate 13-Acetate and Ionomycin cell stimulation cocktail respectively, (eBioscience, UK)) were co-cultured at a 1:1 ratio with tumor cells and tumor cell expression of PD-L1 determined as described above.
  • Silencing of IFN ⁇ R1 expression was achieved by lentiviral transduction of cells with ShRNA (cells were also transduced with non-targeting ShRNA as controls) (Thermo Scientific, UK).
  • Measurement of splenocyte cytokine production was measured by intracellular flow cytometry as described above.
  • Blockade of PD-1 or PD-L1 Enhances the Therapeutic Efficacy of RT
  • RT-mediated increase in tumor cell PD-L1 expression peaks at 72 hours after the last dose of RT and although it declines significantly by 7 days post RT (when compared to expression at days 1 and 3; P ⁇ 0.05 and P ⁇ 0.01 respectively, Mann-Whitney test) remains elevated when compared to NT mice (P ⁇ 0.05, Mann-Whitney test).
  • RT immune response generated following RT may be limited through the PD-1/PD-L1 axis.
  • Local RT delivered as about 10 Gy in 5 daily fractions was found to significantly improve survival in mice bearing established CT26 tumors when compared to NT controls ( FIGS. 1C and D; P ⁇ 0.05 Log-rank; Mantel-Cox test).
  • Our data demonstrate that this RT-mediated local tumor control can be substantially improved through combination with either ⁇ PD-L1 mAb or ⁇ PD-1 mAb ( FIGS. 1C and D; P ⁇ 0.001 Log-rank; Mantel-Cox test).
  • Blockade of PD-L1 also improved response to RT in mice bearing established 4T1 tumors where combined therapy significantly reduced tumor burden by 38% when compared to RT alone ( FIG. 1E ; 10 days post start of therapy; 184.3 ⁇ 13.5 mm 2 vs. 292.8 ⁇ 14.3 mm 2 respectively, P ⁇ 0.01 Mann-Whitney test) and significantly improved survival (P ⁇ 0.001 Log-rank; Mantel-Cox test; data not shown). Similar results were also observed in mice bearing established 4434 melanomas ( FIG. 1F ). Combination therapy with local RT and mAbs targeting either PD-1 or PD-L1 was well tolerated in both BALB/c and C57Bl/6 mice ( FIGS. 8A and B). These preclinical data clearly demonstrate the potential to improve outcome following low dose fractionated RT of established solid tumors through blockade of the PD-1/PD-L1 axis.
  • NK Cells Contribute to Local Tumor Control Following Combination Therapy but Long-Term Survival is Dependent on CD8 + T Cells
  • LTS long term survival
  • CD8 + T cells completely abrogated the therapeutic efficacy of combination RT/ ⁇ PD-L1 mAb therapy (P ⁇ 0.001 Log-rank; Mantel-Cox test). Depletion of immune cell populations was confirmed by flow cytometry on peripheral blood samples ( FIG. 2C ). These data suggest that whilst NK cells may exert some local tumor control this does not impact overall survival and while CD4 + T cells are dispensable or even capable of suppressing responses, CD8 + T cells appear to mediate effective long term tumor control following treatment with RT and ⁇ PD-L1 mAb.
  • splenocytes were harvested from LTS mice that had greater than 100 days of disease free survival and the capacity of CD8 + T cells to produce IFN ⁇ following co-culture with peptide derived from a CT26 tumor associated antigen (AH1: SPSYVYHQF (SEQ ID NO: 91)), control peptide ( ⁇ -galactosidase: TPHARIGL (SEQ ID NO: 93)) or with irradiated CT26 cells was assessed ( FIG. 3B and C).
  • AH1 SPSYVYHQF
  • TPHARIGL TPHARIGL
  • FIG. 4A To identify which cellular populations within the tumor microenvironment were responsible for modulating tumor cell expression of PD-L1 mice received a fractionated RT cycle in combination with CD8, CD4 or NK cell depleting antibodies.
  • CD8 + T cells but not NK cells completely abrogates the RT-mediated upregulation of PD-L1 on tumor cells.
  • FIGS. 4B and C the depletion of CD4 + T cells was found to further augment RT-mediated upregulation of PD-L1 on tumor cells ( ⁇ 2 fold compared to treatment with RT alone).
  • IFN ⁇ R1 IFN- ⁇ -receptor 1
  • NTC ShRNA non-targeting ShRNA
  • PMA phorbol 12-myristate 13-acetate
  • ionomycin-treated splenocytes
  • mice received RT in combination with ⁇ IFN ⁇ blocking antibody (or isotype control).
  • IFN ⁇ blockade reduced tumor cell expression of PD-L1 by 2.6 fold in NT mice to the level observed on CT26 cells cultured in vitro; suggesting adaptive upregulation of PD-L1 occurs following implantation of tumor ( FIGS. 5D and E).
  • the significant upregulation of PD-L1 observed following RT was completely abrogated by IFN ⁇ blockade confirming this as the driver of adaptive tumor cell expression of PD-L1 following RT treatment.
  • mice bearing established CT26 tumors received a fractionated RT cycle of about 10 Gy in 5 fractions with administration of ⁇ PD-L1 mAb commencing either on day 1 of the fractionated RT cycle (schedule A), day 5 of the cycle (schedule B) or 7 days after completion of RT (schedule C) ( FIG. 6A ).
  • No significant difference in overall survival was found between schedule A and B with LTS of 60% and 57 respectively (P>0.05 Log-rank; Mantel-Cox test) ( FIG. 6B and FIG. 10A ).
  • mice received either 3 doses of mAb concurrent with RT or the same with dosing extended (3qw) for an additional 2 weeks. No additional benefit was observed with extended ⁇ PD-L1 mAb administration ( FIG. 11 ).
  • CD4 + helper T cells may be dispensable for the generation of effective CD8 + T cell responses post RT/PD-L1 mAb therapy in our model and that either helper T cells, or more likely Treg, may be actively suppressing IFN ⁇ production in the local tumor milieu. Therefore, the therapeutic potential to enhance anti-tumor responses by Treg depletion may be at least in part attenuated through enhanced tumor cell expression of PD-L1.
  • PD-L1 expression can be modulated by a number of cytokines including type-1 and 2 IFN, TNF ⁇ and TGF ⁇ (16, 22, 30-32).
  • cytokines including type-1 and 2 IFN, TNF ⁇ and TGF ⁇ (16, 22, 30-32).
  • IFN ⁇ R1 or in vivo depletion of IFN ⁇ demonstrates dependence on IFN ⁇ mediated signalling for upregulation of PD-L1, with TNF ⁇ alone incapable of modulating tumor cell PD-L1 expression.
  • IFN ⁇ R1 or in vivo depletion of IFN ⁇ reduces PD-L1 expression on syngeneic tumor cells, matching the expression profile of tumor cells in vitro.
  • this study demonstrates that treatment with fractionated RT leads to upregulation of tumor cell expression of PD-L1 and that blockade of the PD-1/PD-L1 axis can enhance the immune response to fractionated RT in multiple syngeneic mouse models of cancer.
  • Our data suggest that dose scheduling of ⁇ PD-L1 mAb with RT may generate therapeutic immune responses with the capacity to reduce tumor burden and improve survival. This therapeutic combination may be a promising approach for the treatment of many solid malignancies where RT is commonly used and translation to early phase clinical trial is clearly warranted.
  • Patient A has colorectal cancer.
  • patient A receives an effective amount of radiation therapy in five fractions.
  • patient A also receives a therapeutic dose of MEDI4736 on day 1, day 3, and day 5.
  • Patient A repeats this schedule for weeks 2, 3, 4, and 5.
  • Patient B has breast cancer. In week 1, patient B receives an effective amount of radiation therapy. In week 1, patient B also receives a therapeutic dose of MEDI4736 on day 5. Patient repeats this schedule for weeks 3, 5, and 7.
  • Item 1 A method of treating cancer in a patient comprising
  • Item 2 The method of item 1, wherein the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof.
  • Item 3 The method of any one of items 1-2, wherein the dose of radiation therapy is about 11 Gy or lower.
  • Item 4 The method of item 3, wherein the dose of radiation therapy is about 10 Gy or lower.
  • Item 5 The method of any one of items 1-4,wherein the radiation therapy is fractionated radiation therapy.
  • Item 6 The method of item 5, wherein the fractionated radiation therapy comprises from 2 to 7 fractions.
  • Item 7 The method of item 6, wherein the fractionated radiation therapy comprises 5 fractions.
  • Item 8 The method of any one of items 5-7, wherein the radiation therapy fractions are administered in sequential days.
  • Item 9 The method of any one of items 5-8, wherein the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5.
  • Item 10 The method of any one of items 7-9, wherein the radiation therapy comprises about 10 Gy in 5 fractions.
  • Item 11 The method of any one of items 1-10, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 1.
  • Item 12 The method of any one of items 1-11, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 5.
  • Item 13 The method of any one of items 1-12, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
  • Item 14 The method of any one of items 1-13, wherein the at least one PD-1 and/or PD-L1 antagonist is administered 3 times a week.
  • Item 15 The method of any one of items 1-14, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
  • Item 16 The method of any one of items 1-15, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • Item 17 The method of any one of items 1-16, wherein the cancer is melanoma, colorectal cancer, or breast cancer.
  • Item 18 The method of any one of items 1-17, wherein more than one treatment cycle is performed.
  • Item 19 The method of item 18, wherein from 2-8 treatment cycles are performed.
  • Item 20 The method of any one of items 18-19, wherein the treatment cycles are weekly.
  • Item 21 The method of any one of items 18-19, wherein the treatment cycles are every other week.
  • IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186, 2772-2779 (2011).
  • the term about refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
  • the term about generally refers to a range of numerical values (e.g., +/ ⁇ 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result).
  • the term about may include numerical values that are rounded to the nearest significant figure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/013,157, filed Jun. 17, 2014, which is incorporated by reference herein in its entirety for all purposes.
    • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 16, 2015, is named B7H1-275US1_SL.txt and is 101,340 bytes in size.
    • FIELD
  • Methods of treatment for cancer.
    • BACKGROUND
  • Radiation therapy (RT) remains the most important non-surgical treatment in the management of solid malignancies with around 50-60% of all cancer patients receiving this treatment. The inclusion of RT in treatment regimens reduces disease recurrence and improves overall survival in the majority of common cancers (1-3). Although effective, many patients suffer from local recurrence and metastatic disease.
  • In addition to the direct cytoreductive effect of RT, emerging evidence suggests that the generation of anti-tumor immune responses may play an important role in the effectiveness of this treatment (4, 5). RT can lead to expression of ecto-calreticulin on tumor cells as well as the release of several damage-associated molecular patterns (DAMPs) including High Mobility Group Box 1 (HMGB1) and ATP which can lead to recruitment and activation of antigen presenting cells (APCs) and priming of tumor antigen-specific T cell responses (6-10). Despite this immune-escape frequently occurs, with tumor recurrence remaining the leading cause of mortality in patients receiving RT (11). The identification and inhibition of key drivers of immunosuppression may augment anti-tumor immune responses with the potential to improve patient outcome.
  • New insights into treatment failure and more effective RT combination approaches are therefore urgently required.
  • The programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is involved in the maintenance of peripheral tolerance and the modulation of acute inflammatory responses through inhibition of T cell function and through apoptosis of activated T cells (12, 13). In addition to binding PD-1, PD-L1 can also suppress T cell function through interaction with CD80 (14). Expression of PD-L1 is inducible and thought to respond to local inflammatory milieu, particularly type I and II interferon (IFN) (12, 15, 16). Although barely detectable in most normal tissues, expression of PD-L1 has been described in multiple malignancies (reviewed in (17)). Importantly, recent clinical studies with either PD-1 or PD-L1 targeting monoclonal antibodies (mAb) have demonstrated encouraging responses in patients with advanced disease (18-21).
  • A dosing strategy for combining radiation therapy and a PD-1 and/or PD-L1antagonist is desired to create maximal benefit for patients suffering from cancer.
    • SUMMARY
  • In accordance with the description, a method of treating cancer in a patient comprises
      • a. administering at least one dose of radiation therapy; and
      • b. administering at least one PD-1 and/or PD-L1 antagonist,
        • wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
  • In another mode, the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof.
  • In one aspect, the radiation therapy is fractionated radiation therapy. In one mode, the fractionated radiation therapy comprises from 2 to 7 fractions. In another mode, the fractionated radiation therapy comprises 5 fractions.
  • In one embodiment, the radiation therapy fractions are administered in sequential days. In another embodiment, the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5. In one embodiment, the radiation therapy comprises about 10 Gy in 5 fractions.
  • In one aspect, the at least one PD-1 and/or PD-L1 antagonist is administered on at least day 1 and/or on day 5. In one mode, the at least one PD-1 and/or PD-L1 antagonist is administered multiple times. For example, the at least one PD-1 and/or PD-L1 antagonist may be administered 3 times a week.
  • In one embodiment, the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
  • In another embodiment, the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • In one aspect, the cancer is melanoma, colorectal cancer, or breast cancer. In another aspect, more than one treatment cycle is performed. In a further aspect, from 2-8 treatment cycles are performed. In one mode, treatment cycles are weekly or every other week.
  • Additional objects and advantages will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice. The objects and advantages will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claims.
  • The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate one (several) embodiment(s) and together with the description, serve to explain the principles described herein.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A-1F illustrate that blockade of the PD-1/PD-L1 axis potentiates the activity of fractionated radiation therapy. A and B, median fluorescence intensity (FIG. 1A) and representative histograms (FIG. 1B) of PD-L1 expression on CT26 cells isolated from tumors 1, 3 or 7 days after treatment with about 10 Gy in 5 daily fractions of 2 Gy. C and D, CT26 tumor bearing mice received about 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with either αPD-1 (FIG. 1C) or αPD-L1 (FIG. 1D) mAb dosed at 10 mg/kg 3qw for up to 3 weeks. FIG. 1E, tumor volumes 10 days after the start of therapy in 4T1 tumor bearing mice that received 20 Gy RT delivered in 5 daily fractions of 4 Gy either alone or in combination with αPD-L1 mAb. FIG. 1F, 4434 tumor bearing mice received about 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with αPD-L1 mAb. Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments. A, E and F show mean±SEM. *, P<0.05 **, P<0.01, Mann-Whitney test. In FIGS. 1C and 1D, *, denotes significance when compared to control mice. +, denotes significance when compared to monotherapy. ***/+++, P<0.001, Log-rank (Mantel-Cox) test.
  • FIGS. 2A-2C demonstrate that therapeutic activity of fractionated RT and αPD-L1 mAb combination is dependent on the activity of CD8+ T-lymphocytes. FIG. 2A, tumor volume on day of therapy, 7 and 11 days post combination therapy with 5 fractions of 2 Gy and αPD-L1 mAb. Immune cell subsets (either CD8, CD4 or NK cell) were depleted 1 day prior to therapy with depletion maintained for 2 weeks. ***, P>0.001, *, P>0.01, *, P>0.05, Mann-Whitney test. FIG. 2B, Survival curve. ***/+++, P<0.001, Log-rank (Mantel-Cox) test. Data representative of 10 mice per cohort. FIG. 2C, representative density plots of peripheral blood confirming depletion of immune cell subsets.
  • FIGS. 3A-3C show that fractionated RT and αPD-L1 mAb combination generates protective immunological memory. FIG. 3A, Survival curve of LTS mice following contralateral rechallenge with 5×105 CT26 cells. * P<0.05 compared to control mice (log-rank; Mantel-Cox test). FIG. 3B, representative dot blot of IFNγ production by CD8+ T cells isolated from either tumor naïve, or LTS mice originally treated with RT and αPD-L1 mAb. FIG. 3C, frequency of IFNγ+ CD8+ T cells isolated from either tumor naïve, or LTS mice originally treated with RT and αPD-L1 mAb following co-culture with either H2-Ld restricted peptides (AH1 (SPSYVYHQF) (SEQ ID NO: 91); a defined CT26 tumor-associated antigen or β-galactosidase (TPHPARIGL) (SEQ ID NO: 92); control peptide of prokaryotic origin) or 50 Gy irradiated CT26 cells for 5 days, followed by priming with 50 Gy irradiated CT26 cells. * P<0.05 (Mann-Whitney test). Data representative of 2 independent experiments.
  • FIGS. 4A-4C illustrate that fractionated RT increases tumor cell PD-L1 expression in vivo and is dependent on CD8+ T cells. FIG. 4A, Expression of PD-L1 on CT26 cells post treatment with RT (2.5-10Gy) in vitro. FIGS. 4B and 4C, Representative contour plots (FIG. 4B) and median fluorescence intensity (FIG. 4C) of PD-L1 expression on CT26 cells (gated as CD45− cells) isolated from tumors 3 days after receiving about 10 Gy in 5 daily fractions of 2Gy in combination with either CD8, CD4 or NK cell depleting antibodies. * P<0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at least 2 independent experiments.
  • FIGS. 5A-5E show that CD8+ T cell production of IFNγ is responsible for the upregulation of PD-L1 expression on tumor cells following fractionated RT. FIG. 5A, Expression of PD-L1 on wild-type CT26 tumor cells (WT), or cells transduced with either a non-targeting control (NTC) or IFNγR1 ShRNA following co-culture for 24 hours with either 20 ng/ml IFNγ, TNFα or a combination of both cytokines. FIG. 5B, representative density plots showing expression of IFNγ and TNFα by CD8+ T cells following treatment with either PBS or phorbol 12-myristate 13-acetate (PMA) and ionomycin, FIG. 5C, Frequency of PD-L1 positive CT26 tumor cells (WT, NTC ShRNA or IFNγR1 ShRNA) following 24 hour co-culture with either PBS or PMA/ionomycin activated splenocytes. n/s=P>0.05, *** P<0.001 ** P<0.01 (2-tailed Student t test). FIGS. 5D and 5E, representative contour plots (FIG. 5D) and median fluorescence intensity (FIG. 5E) of PD-L1 expression on CT26 tumor cells following treatment with RT (about 10 Gy in 5 fractions) in the presence of an αIFNγ blocking mAb (or isotype control) in vivo. ** P<0.01, (Mann-Whitney test). Experimental groups contained at least 5 mice.
  • FIGS. 6A-6D demonstrate that dosing schedule impacts outcomes with RT potentiation only observed with concurrent but not sequential αPD-L1 mAb therapy. FIG. 6A, Schema for dose-scheduling studies. Mice received fractionated dose RT (as about 10 Gy in 5 daily fractions of 2 Gy) alone or in combination with αPD-L1 mAb starting either on day 1 of RT cycle (schedule A), day 5 of RT cycle (schedule B) or 7 days post the last dose of RT (Schedule C). FIG. 6B, Survival curves of therapy. ++, P<0.01 compared to monotherapy (log-rank; Mantel-Cox test). FIGS. 6C and 6D, Expression of PD-1 on CD4+ (FIG. 6C) and CD8+ (FIG. 6D) T cells 24 hours and 7 days after the last dose of RT. * P<0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at least 2 independent experiments.
  • FIG. 7 shows blockade of both PD-1 and PD-L1 does not further enhance efficacy in combination with fractionated RT in CT26-tumor bearing mice. A) Survival curve following fractionated dose RT (as 10 Gy in 5 daily fractions of 2 Gy) alone or in combination with αPD-1, αPD-L1 or a combination of both mAb dosed 3qw for 3 weeks. n/s, P>0.05, log-rank; Mantel-Cox test. Experimental groups contained at least 5 mice and are representative of at 2 independent experiments.
  • FIGS. 8A-8B show combination therapy with fractionated RT and either αPD-1 or αPD-L1 mAb is well tolerated in mice. CT26 tumor bearing mice received 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with αPD-L1 mAb dosed at 10 mg/kg 3qw either for 3 weeks or 1 week. Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments. n/s, P>0.05, Mann-Whitney test.
  • FIGS. 9A-9C illustrate that treatment of tumor cells with αPD-1 or αPD-L1 mAb does not sensitise to radiation-induced cell death in vitro. Clonogenic survival curves for CT26 cells (FIG. 9A), 4T1 cells (FIG. 9B) and 4434 cells (FIG. 9C) treated with RT (2.5-10Gy) in the presence absence of 2 μg/ml αPD1 or αPD-L1.
  • FIGS. 10A-10C show that the dosing schedule impacts outcome. FIG. 10A) tumour volumes following fractionated dose RT (as 10 Gy in 5 daily fractions of 2 Gy) alone or in combination with αPD-L1 mAb starting either on day 1 of RT cycle (schedule A), day 5 of RT cycle (schedule B) or 7 days post the last dose of RT (Schedule C). FIGS. 10B and 10C) tumour volumes of RT-treated mice demonstrating equivalent tumor volumes across different dosing schedules. n/s, P>0.05 (Mann-Whitney test). Experimental groups contained at least 5 mice and are representative of at 2 independent experiments.
  • FIG. 11 shows that acute versus chronic administration of αPD-L1 mAb does not impact efficacy of combination therapy. A, CT26 tumor bearing mice received 10 Gy RT delivered in 5 daily fractions of 2 Gy either alone or in combination with αPD-L1 mAb dosed at 10 mg/kg 3qw either for 3 weeks or 1 week. Experimental groups contained at least 7 mice and are representative of at least 2 independent experiments. n/s, P>0.05, log-rank; Mantel-Cox test.
    •  DESCRIPTION OF THE SEQUENCES
  • Table 1 provides a listing of certain sequences referenced in present embodiments. CDRs have been indicated in bold and underlining.
  • TABLE 1
    Description Sequence SEQ ID NO
    2.7A4 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS TYSMN WVRQAPGK  1
    GLEWVS SISSSGDYIYYADSVKG RFTISRDNAKNSLFLQMNSL
    KAEDTAVYYCAR DLVTSMVAFDY WGQGTLVTVSS
    2.7A4 VL TC SGDALPQKYVF WYQQKSGQAPVLVIY EDSKRPS GIPERFSG  2
    SSSGTMATLTISGAQVEDEADYYC YSTDRSGNHRV FGGGTRLT
    VL
    2.9D10 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFS SYWMS WVRQAPGK  3
    GLEWVA NIKQDGGEQYYVDSVKG RFTISRDNAKNSLYLQMNSL
    RAEDTAVYYCAR DWNYGYYDMDV WGQGTTVTVSS
    2.9D10 VL EIVLTQSPGTLSLSPGERATLSC RASQSVSSNYLA WFQQKPGQ  4
    APRLLIF GTSSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYC QQYGSSIFT FGPGTKVDIK
    2.14H9 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFS RYWMS WVRQAPGK  5
    GLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSL
    RAEDTAVYYCAR EGGWFGELAFDY WGQGTLVTVSS
    2.14H9 VL EIVLTQSPGTLSLSPGERATLSC RASQRVSSSYLA WYQQKPGQ  6
    APRLLIY DASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYC QQYGSLPWT FGQGTEVEIK
    2.20A8 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFS NYAMS WVRQAPGK  7
    GLEWVS AIRGSGGSTYYADSVKG RFTISRDNSKNTLYLQMN
    SLRAEDTAVYYCAK DLHYDSSGYLDY WGQGTLVTVSS
    2.20A8 VL DIQMTQSPSSVSASVGDRVTITC RASQGIRSWLA WYQQKPGKA  8
    PKLLIY AISRLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YC QQANSFPLT FGGGTKVEIK
    3.15G8 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFS SYWMS WVRQAPGK  9
    GLEWVA NIKQDGGEKYYVDSVKG RFTISRDNAKNSLFLQMNSL
    RAEDTAVYYCAR VQLYSDY FDYWGQGTLVTVSS
    3.15G8 VL DIQMTQSPSSVSASVGDRVTITC RASQGISSWLA WYQQKSGKA 10
    PKLLIY AASGLQS GVPSRFSGSGSGTDFTLTISSLQPEDLATY
    YC QQSHSLPPT FGQGTKVEIK
    3.18G1 VH EVQLLESGGDLVQPGGSLRLSCAASGFTFN SYAMS WVRQAPGK 11
    GLEWVS TISGSGGFTFSADSVKG RFTISRDNSKNTLFLQMNSL
    RVEDSAVYSCAK VLVGFNNGCWDY WGQGTLVTVSS
    3.18G1 VL SYVLTQPPSVSVAPGQTARITC GGNNIGSKSVH WYQQKPGQAP 12
    VLVVY DDSDRPS GIPERFSGSNSGNTATLTISRVEAGDEADYY
    C QVWDSSNDHVV FGGGTKLTVL
    2.7A4 OPT VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS TYSMN WVRQAPGK 13
    GLEWVS SISSSGDYIYYADSVKG RFTISRDNAKNSLYLQMNSL
    RAEDTAVYYCAR DLVTSMVAFDY WGQGTLVTVSS
    2.7A4 OPT VL SYELTQPPSVSVSPGQTARITC SGDALPQKYVF WYQQKSGQAP 14
    VLVIY EDSKRPS GIPERFSGSSSGTMATLTISGAQVEDEADYY
    C YSTDRSGNHRV FGGGTKLTVL
    2.14H9 OPT EVQLVESGGGLVQPGGSLRLSCAASGFTFS RYWMS WVRQAPGK 15
    VH GLEWVA NIKQDGSEKYYVDSVKG RFTISRDNAKNSLYLQMNSL
    RAEDTAVYYCAR EGGWFGELAFDY WGQGTLVTVSS
    2.14H9 OPT EIVLTQSPGTLSLSPGERATLSC RASQRVSSSYLA WYQQKPGQ 16
    VH APRLLIY DASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYC QQYGSLPWT FGQGTKVEIK
    1E12 VH EVKLQESGPS LVKPSQTLSL TCSVT GYSIT SDYWN WIRKF 17
    (anti-PD-L1) PGNKLEYVG Y ISYTGSTYYN PSLKS RISIT RDTSKNQYYL
    QLNSVTSEDT ATYYCAR YGG WLSPF DYWGQ GTTLTVSS
    1E12 VL DIVMTQSHKL MSTSVGDRVS ITC KASQDVG TAVA WYQQKP 18
    (anti-PD-L1) GQSPKLLIY W ASTRHT GVPD RFTGSGSGTD FTLTISNVQS
    EDLADYFC QQ DSSYPLT FGA GTKVELK
    1F4 VH EVQLQESGPG LVAPSQSLSI TCTVS GFSLT TYSIN WIRQP 19
    (anti-PD-L1) PGKGLEWLG V MWAGGGTNSN SVLKS RLIIS KDNSKSQVFL
    KMNSLQTDDT ARYYCAR YYG NSPYYAI DYW GQGTSVTVSS
    1F4 VL DIVTTQSHKL MSTSVGDRVS ITC KASQDVG TAVA WYQQKP 20
    (anti-PD-L1) GQSPKLLIY W ASTRHT GVPD RFTGSGSGTD FTLTISNVQS
    EDLADYFC QQ DSSYPLT FGA GTKVELK
    2G11 VH EVKLQESGPS LVKPSQTLSL TCSVT GYSII SDYWN WIRKF 21
    (anti-PD-L1) PGNKLEYLG Y ISYTGSTYYN PSLKS RISIT RDTSKNQYYL
    QLNSVTTEDT ATYYCA RRGG WLLPF DYWGQ GTTLTVSS
    2G11 VL DIVMTQSPSS LAVSVGEKVS MGC KSSQSLL YSSNQKNSLA 22
    (anti-PD-L1) WYQQKPGQSP KLLID WASTR ES GVPDRFTG SGSGTDFTLT
    ISSVKAEDLA VYYC QQYYGY PLT FGAGTKL ELK
    3B6 VH EVKLQESGPS LVKPGASVKL SCKAS GYTFT SYDIN WVKQR 23
    (anti-PD-L1) PGQGLEWIG W IFPRDNNTKY NENFKG KATL TVDTSSTTAY
    MELHSLTSED SAVYFCTK EN WVGDF DYWGQ GTTLTLSS
    3B6 VL DIVMTQSPAI MSASPGEKVT MTCSASSSIR YMHWYQQKPG 24
    (anti-PD-L1) TSPKRWIS DT SKLTS GVPAR FSGSGSGTSY ALTISSMEAE
    DAATYYC HQR SSYPWTF GGG TKLEIK
    3D10 VH EVQLQQSGPD LVTPGASVRI SCQAS GYTFP DYYMN WVKQS 25
    (anti-PD-L1) HGKSLEWIG D IDPNYGGTTY NQKFKG KAIL TVDRSSSTAY
    MELRSLTSED SAVYYCAR GA L TDWGQGTSL TVSS
    3D10 VL QIVLSQSPAI LSASPGEKVT MTC RASSSVS YIY WFQQKPG 26
    (anti-PD-L1) SSPKPWIY AT FNLAS GVPAR FSGSGSGTSY SLTISRVETE
    DAATYYC QQW SNNPLT FGAG TKLELK
    1E3 VH EVQLQQSGPV LVKPGASVKM SCKAS GYTFT DYYMN WVKQS 27
    (anti-PD-1) HGKSLEWIG N INPYNGGTTY NQKFKG KATL TVDKSSRTAY
    MEINSLTSED SAVYYCAR GR IYDGSLDY WG QGTALTVSS
    1E3 VL DIQMTQFPSS LCASQGGKVT VTC KASQDIN NYMA WYQHKP 28
    (anti-PD-1) GKGPRLLIH Y TSTLLS GIPS RFSGSGSGRD YSFSISNLEP
    EDIATYYC LQ YDNLWT FGGG TKLEIK
    1E8 VH QVQLQQSGAE LAKPGASVRL SCKAS GYTFT NYWMH WVKQR 29
    (anti-PD-1) PGQGLEWIG H INPSSGFTTY NQNFKD KATL TADKSSNTAY
    MQLSSLTYED SAVYFCAR ED YDVDY WGQGT TLTVSS
    1E8 VL DIVMTQSQKF MSTSVGDRVS VTC KASQSVD TNVA WYQQKP 30
    (anti-PD-1) GQSPKALIF S ASYRYS GVPD RFTGSGSGTD FTLTINSVQS
    EDLAEYFC QQ YNSYPY TFGSG TKLEIK
    1H3VH EVQLVESGGG LVKPGGSLKL SCAAS GFTFS DYGMH WVRQA 31
    (anti-PD-1) PEKGLEWVA Y ISSGSYTIYY TDTVKG RFTI SRDNAKNTLF
    LQMTSLRSED TAMYYCAR RG YGSFYEYYFD 
    Y WGQGTTLTV SS
    1H3 VL QIVLTQSPAL MSASPGEKVT MTC SASSSVS YMY WYQQKPR 32
    (anti-PD-1) SSPKPWIY LT SNLAS GVPAR FSGSGSGTSY SLTISSMEAE
    DAATYYC QQW SSNPFT FGSG TKLEIK
    Humanized QVQLVQSGAEVKKPGASVKVSCKASGYTFPDYYMNWVRQAPGQ 33
    Anti-Human GLEWMGDIDPNYGGTNYAQKFQGRVTMTRDTSISTAYMELSRL
    B7-H1 RSDDTAVYYCARGALTDWGQGTMVTVSS
    Heavy Chain
    HC1_1
    Humanized QVQLVQSGAEVKKPGASVKVSCKASGYTFPDYYMNWVRQAPGQ 34
    Anti-Human SLEWMGDIDPNYGGTNYNQKFQGRVTMTRDTSISTAYMELSRL
    B7-H1 RSDDTAVYYCARGALTDWGQGTMVTVSS
    Heavy Chain
    HC1_2
    Humanized EVQLVQSGAEVKKPGASVKVSCKASGYTFPDYYMNWVRQAPGQ 35
    Anti-Human SLEWMGDIDPNYGGTNYNQKFQGRVTMTVDRSSSTAYMELSRL
    B7-H1 RSDDTAVYYCARGALTDWGQGTMVTVSS
    Heavy Chain
    HC1_3
    Humanized EVQLVESGGGLVQPGRSLRLSCTASGYTFPDYYMNWVRQAPGK 36
    Anti-Human GLEWVGDIDPNYGGTTYAASVKGRFTISVDRSKSIAYLQMSSL
    B7-H1 KTEDTAVYYCTRGALTDWGQGTMVTVSS
    Heavy Chain
    HC2_1
    Humanized EVQLVESGGGLVQPGRSLRLSCTASGYTFPDYYMNWVRQAPGK 37
    Anti-Human GLEWVGDIDPNYGGTTYNASVKGRFTISVDRSKSIAYLQMSSL
    B7-H1 KTEDTAVYYCARGALTDWGQGTMVTVSS
    Heavy Chain
    HC2_2
    Humanized EVQLVESGGGLVQPGRSLRLSCTASGYTFPDYYMNWVRQAPGK 38
    Anti-Human GLEWVGDIDPNYGGTTYNQSVKGRFTISVDRSKSIAYLQMSSL
    B7-H1 KTEDTAVYYCARGALTDWGQGTMVTVSS
    Heavy Chain
    HC2_3
    Humanized EIVLTQSPATLSLSPGERATLSCRASSSVSYIYWFQQKPGQAP 39
    Anti-Human RLLIYAAFNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain 
    LC1_1
    Humanized EIVLTQSPATLSLSPGERATLSCRASSSVSYIYWFQQKPGQSP 40
    Anti-Human RPLIYAAFNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain
    LC1_2
    Humanized QIVLTQSPATLSLSPGERATLSCRASSSVSYIYWFQQKPGQSP 41
    Anti-Human RPLIYATFNLASGIPARFSGSGSGTSYTLTISRLEPEDFAVYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain
    LC1_3
    Humanized DIQLTQSPSSLSASVGDRVTITCRASSGVSYIYWFQQKPGKAP 42
    Anti-Human KLLIYAAFNLASGVPSRFSGSGSGTEYTLTISSLQPEDFATYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain
    LC2_1
    Humanized DIQLTQSPSSLSASVGDRVTITCRASSGVSYIYWFQQKPGKAP 43
    Anti-Human KPLIYAAFNLASGVPSRFSGSGSGTEYTLTISSLQPEDFATYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain
    LC2_2
    Humanized DIQLTQSPSILSASVGDRVTITCRASSSVSYIYWFQQKPGKAP 44
    Anti-Human KPLIYATFNLASGVPSRFSGSGSGTSYTLTISSLQPEDFATYY
    B7-H1 CQQWSNNPLTFGQGTKVEIK
    Light Chain
    LC2_3
    Humanized EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGK 45
    Anti-Human GLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNTLYLQMSSL
    PD-1 RAEDTAVYYCARRGYGSFYEYYFDYWGQGTTVTVSS
    Heavy Chain
    HC1_1
    Humanized EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGK 46
    Anti-Human GLEWVAYISSGSYTIYYADSVKGRFTISRDNAKNTLYLQMSSL
    PD-1 RAEDTAVYYCARRGYGSFYEYYFDYWGQGTTVTVSS
    Heavy Chain
    HC1_2
    Humanized EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGK 47
    Anti-Human GLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNTLYLQMSSL
    PD-1 RAEDTAVYYCARRGYGSFYEYYFDYWGQGTTVTVSS*
    Heavy Chain
    HC1_3
    Humanized QVQLVQSGAEVKKPGASVKVSCKASGFTFSDYGMHWVRQAPGQ 48
    Anti-Human RLEWMGYISSGSSTIYYSQKFQGRVTITRDNSASTLYMELSSL
    PD-1 RSEDTAVYYCARRGYGSFYEYYFDYWGQGTTLTVSS
    Heavy Chain
    HC2_1
    Humanized EVQLVQSGAEVKKPGASVKVSCAASGFTFSDYGMHWVRQAPGQ 49
    Anti-Human RLEWMGYISSGSYTIYYSQKFQGRVTITRDNSASTLYMELSSL
    PD-1 RSEDTAVYYCARRGYGSFYEYYFDYWGQGTTLTVSS
    Heavy Chain
    HC2_2
    Humanized EVQLVQSGAEVKKPGASVKVSCAASGFTFSDYGMHWVRQAPGQ 50
    Anti-Human RLEWVAYISSGSYTIYYSQKFQGRVTITRDNSASTLYMELSSL
    PD-1 RSEDTAVYYCARRGYGSFYEYYFDYWGQGTTLTVSS
    Heavy Chain
    HC2_3
    Humanized EIVLTQSPATLSLSPGERATLSCRASSSVSYMYWYQQKPGQAP 51
    Anti-Human RLLIYLASNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYY
    PD-1 CQQWSSNPFTFGQGTKLEIK
    Light Chain
    LC1_1
    Humanized QIVLTQSPATLSLSPGERATLSCSASSSVSYMYWYQQKPGQAP 52
    Anti-Human RLLIYLTSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYY
    PD-1 CQQWSSNPFTFGQGTKLEIK
    Light Chain
    LC1_2
    Humanized DIQLTQSPSSLSASVGDRVTITCRASSSVSYMYWYQQKPGKAP 53
    Anti-Human KLLIYLASNLASGVPSRFSGSGSGTEYTLTISSLEPEDFATYY
    PD-1 CQQWSSNPFTFGQGTKLEIK
    Light Chain
    LC2_1
    Humanized QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAP 54
    Anti-Human KLLIYLTSNLASGVPSRFSGSGSGTEYTLTISSLEPEDFATYY
    PD-1 CQQWSSNPFTFGQGTKLEIK
    Light Chain
    LC2_2
    Certain
    Specific                   Light       Heavy
    Combinations Antibody          Chain       Chain
    h1H3 Var 1        LC1_1       HC1_1    
    h1H3 Var 2        LC1_1       HC1_2 
    h1H3 Var 3        LC1_1       HC1_3 
    h1H3 Var 4        LC1_2       HC1_1
    h1H3 Var 5        LC1_2       HC1_2 
    h1H3 Var 6        LC1_2       HC1_3 
    h1H3 Var 7        LC2_1       HC2_1
    h1H3 Var 8        LC2_1       HC2_2
    h1H3 Var 9        LC2_1       HC2_3 
    h1H3 Var 10       LC2_2       HC2_1  
    h1H3 Var 11       LC2_2       HC2_2 
    h1H3 Var 12       LC2_2       HC2_2  
    h1H3 Var 13       LC1_1       HC2_1
    h1H3 Var 14       LC2_1       HC1_1  
    17D8 VH QVQLVESGGDVVQPGGSLRLSCAASGVAFSNYGMHWVRQAPGK 55
    (#1) GLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNMLYLQMNSL
    RAEDTAMYYCARNDDYWGQGTLVTVSS
    17D8 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 56
    (#8) PRLIIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPLTFGGGTKVEIK
    2D3 VH QVQLVESGGDVVQPGRSLRLSCAASGLTFTNYGFHWVRQAPGK 57
    (#2) GLEWVAVIWYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNNL
    RAEDTAVYYCATGDDYWGQGTLVTVSS
    2D3 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 58
    (#9) PRLLIYDTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPLTFGGGTKVEIK
    4H1 VH QVYLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGK 59
    3 GLEWVALIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMTSL
    RVEDTAVYYCASNVDHWGQGTLVTVSS
    4H1 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 60
    10 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQSSNWPRTFGQGTKVEIK
    5C4 VH QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGK 61
    4 GLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSL
    BMS-936558 RAEDTAVYYCATNDDYWGQGTLVTVSS
    5C4 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 62
    11 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    BMS-936558 YCQQSSNWPRTFGQGTKVEIK
    4A11 VH QLQLQESGPGLVKPSETLSLTCTVSGGSLSRSSFFWGW1RQPP 63
    5 GKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
    VTAADTAVYYCVRDYDILTGDEDYWGQGTLVTVSS
    4A11 VL DIQMTQSPSSLSASVGDRVSITCRASQGISSWLAWYQQKPEKA 64
    12 PKSLIYAASNLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQYYSYPRTFGQGTKVEIK
    7D3 VH QVQLVESGGGVVQPGRSLRLSCTTSGITFSSYGFHWVRQAPGK 65
    6 GLEWVAVIWYDGSKKYYADSVKGRFTLSRDDSKNTLYLQMNSL
    RAEDTAVYYCVTGDDYWGQGTLVTVSS
    7D3 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 66
    13 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPLTFGGGTKVEIK
    5F4 VH QLQLQESGPGLVKPSETLSLTCSVSGGSLSRSSYFWGWIRQPP 67
    7 GKGLEWIASIFYSGETYFNPSLKSRVTISVDTSRNQFSLKLSS
    VTAADTAVYYCARDYDILTGDEDYWGQGTLVTVSS
    5F4 VL DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKA 68
    14 PKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQYYSYPRTFGQGTKVEIK
    3G10 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYGFSWVRQAPGQ 69
    15 GLEWMGWITAYNGNTNYAQKLQGRVTMTTDTSTSTVYMELRSL
    RSDDTAVYYCARDYFYGMDVWGQGTTVTVSS
    3G10 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQA 70
    25 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPRTFGQGTKVEIK
    12A4 VH QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQ 71
    16 GLEWMGGIIPIFGKAHYAQKFQGRVTITADESTSTAYMELSSL
    BMS-936559 RSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS
    12A4 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 72
    26 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    BMS-93655 Y
    10A5 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDVHWVRQAPGQ 73
    17 RLEWMGWLHADTGITKFSQKFQGRVTITRDTSASTAYMELSSL
    RSEDTAVYYCARERIQLWFDYWGQGTLVTVSS
    10A5 VL DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKA 74
    27 PKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQYNSYPYTFGQGTKLEIK
    5F8 VH QVQLVQSGAEVKKPGSSVKVSCKVSGGIFSTYAINWVRQAPGQ 75
    18 GLEWMGGIIPIFGTANHAQKFQGRVTITADESTSTAYMELSSL
    RSEDTAVYYCARDQGIAAALFDYWGQGTLVTVSS
    5F8 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ 76
    28 APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYCQQYGSSPWTFGQGTKVEIK
    10H10 VH EVQLVESGGGLVQPGRSLRLSCAVSGFTFDDYVVHWVRQAPGK 77
    19 GLEWVSGISGNSGNIGYADSVKGRFTISRDNAKNSLYLQMNSL
    RAEDTALYYCAVPFDYWGQGTLVTVSS
    10H10 DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKA 78
    29 PKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQYNSYPYTFGQGTKLEIK
    1B12 VH QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSSYAISWVRQAPGQ 79
    20 GLEWMGGIIPIFGRAHYAQKFQGRVTITADESTSTAYMELSSL
    RSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS
    1B12 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 80
    30 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPTFGQGTKVEIK
    7H1 VH QVQLVQSGAEVKKPGSSVKVSCKTSGGTFSSYAISWVRQAPGQ 81
    21 GLEWMGGIIPIFGKAHYAQKFQGRVTITADESTTTAYMELSSL
    RSEDTAVYYCARKYDYVSGSPFGMDVWGQGTTVTVSS
    7H1 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 82
    31 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPTFGQGTKVEIK*
    11E6 VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQ 83
    22 GLEWMGGIIPIFGSANYAQKFQDRVTITADESTSAAYMELSSL
    RSEDTAVYYCARDSSGWSRYYMDVWGQGTTVTVSS
    11E6 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ 84
    32 APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYCQQYGSSPFGGGTKVEIK*
    12B7 VH QVQLVQSGAEVKEPGSSVKVSCKASGGTFNSYAISWVRQAPGQ 85
    23 GLEWMGGIIPLFGIAHYAQKFQGRVTITADESTNTAYMDLSSL
    RSEDTAVYYCARKYSYVSGSPFGMDVWGQGTTVTVSS
    12B7 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA 86
    33 PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQRSNWPTFGQGTRLEIK
    13G4 VH EVQLVESGGGLVQPGRSLRLSCAASGITFDDYGMHWVRQAPGK 87
    24 GLEWVSGISWNRGRIEYADSVKGRFTISRDNAKNSLYLQMNSL
    RAEDTALYYCAKGRFRYFDWFLDYWGQGTLVTVSS
    13G4 AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKA 88
    34 PKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQFNSYPFTFGPGTKVDIK
    28-8 VH METGLRWLLLVAVLKGVQCLSVEESGGRLVTPGTPLTLTCTAS 89
    35 GFTITNYHMFWVRQAPGKGLEWIGVITSSGIGSSSTTYYATWA
    KGRFTISKTSTTVNLRITSPTTEDTATYFCARDYFTNTYYALD
    IWGPGTLVTVSS
    28-8 VL MDTRAPTQLLGLLLLWLPGARCALVMTQTPSSTSTAVGGTVTI 90
    36 KCQASQSISVYLAWYQQKPGQPPKLLIYSASTLASGVPSRFKG
    SRSGTEYTLTISGVQREDAATYYCLGSAGS
    • DESCRIPTION OF THE EMBODIMENTS I. Methods of Treatment
  • The present methods encompass treatment of cancer employing at least one dose or radiation therapy and at least one dose of at least one PD-1 and/or PD-L1 antagonist. For instance, a method of treating cancer in a patient may include administering at least one dose of radiation therapy and administering at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
  • The method of treating cancer may be administered once (as a single treatment cycle) or it may be administered more than once (i.e., with multiple treatment cycles), such as on a weekly, every other week, every three weeks, or every month cycle. If the method is administered more than once, it may be administered 2, 3, 4, 5, 6, 7, or 8 times, or more.
  • While not being bound by theory, in a range of established syngeneic tumor models we found that low doses of fractionated RT led to upregulation of tumor cell expression of PD-L1 in vivo. We show that fractionated RT delivered in combination with αPD-1 or αPD-L1 mAbs generated effective anti-tumor CD8+ responses, which improved local tumor control and long-term survival, and protected against tumor rechallenge by the induction of a tumor antigen-specific memory immune response. CD8+ T cell production of IFNγ was found to be responsible for the upregulation of PD-L1 on tumor cells following fractionated RT. Furthermore, scheduling of anti-PD-L1 mAb relative to the delivery of fractionated RT appeared to affect therapeutic outcome; with administration of the antagonist on the same day as RT or up to and including 4 days after the first dose of fractionated RT showing benefit over administration of the antagonist more than 7 days after the conclusion of radiation therapy. And, while not being bound by theory, upregulation of tumor cell PD-L1 expression in response to low doses of fractionated RT, as used routinely in the clinic, appears to be a mechanism of adaptive immunological resistance by tumor cells; with the PD-L1/PD-1 signalling axis therefore potentially contributing to RT treatment failure. Combination therapy with RT and blockade of the PD-1/PD-L1 signalling axis has the potential to overcome this resistance but, based on our preclinical studies, dosage timing impacts the treatment results, providing important new insights for translation to the clinic.
  • A. PD-1 and/or PD-L1 Antagonists for Use in Methods of Treatment
  • In one embodiment, the at least one PD-1 and/or PD-L1 antagonist for use the present methods is an anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof.
  • In one aspect, the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later. For example, in one aspect, if radiation therapy is provided on day 1 of a treatment cycle, the at least one PD-1 and/or PD-L1 antagonist may also be administered on day 1 of the treatment cycle (i.e., the same day as a dose of radiation therapy). In another aspect, if radiation therapy is provided on day 1 of a treatment cycle, the at least one PD-1 and/or PD-L1 antagonist is administered on day 5 (i.e., 4 days later). In a further aspect, the PD-1 and/or PD-L1 antagonist may be administered on day 1, day 2, day 3, day 4, day 5, day 6, and/or day 7 of a treatment cycle (including both single and multiple treatment schedules).
  • In one embodiment, the at least one PD-1 and/or PD-L1 antagonist is administered multiple times in a treatment cycle. In another embodiment, the at least one PD-1 and/or PD-L1 antagonist is administered 2, 3, 4, 5 or more times in a treatment cycle. For example, the antagonist may be administered three times a week for a one-week treatment cycle, or three times a week for a treatment cycle with two or more weeks as described above.
  • In one aspect, the antibody or functional part thereof is chosen from those disclosed in US Publication 2010/0028330, which is incorporated by reference for the teaching of these antibodies and functional parts thereof. In one embodiment, the antibody if MEDI4736.
  • In another embodiment, the anti-PD-1 and/or anti-PD-L1 antibody is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • The antibodies or functional parts thereof are administered in therapeutically effective amounts. Generally, a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition of the subject. A therapeutically effective amount of an antibody or functional part thereof ranges from about 0.001 to about 30 mg/kg body weight, from about 0.01 to about 25 mg/kg body weight, from about 0.1 to about 20 mg/kg body weight, or from about 1 to about 10 mg/kg. The dosage may be adjusted, as necessary, to suit observed effects of the treatment. The appropriate dose is chosen based on clinical indications by a treating physician.
  • The antibodies may be given as a bolus dose, to maximize the circulating levels of antibodies for the greatest length of time after the dose. Continuous infusion may also be used after the bolus dose.
  • As used herein, the term antibody or functional part thereof is used in the broadest sense. It may be man-made such as monoclonal antibodies (mAbs) produced by conventional hybridoma technology, recombinant technology and/or a functional fragment thereof. It may include both intact immunoglobulin molecules for example a polyclonal antibody, a monoclonal antibody (mAb), a monospecific antibody, a bispecific antibody, a polyspecific antibody, a human antibody, a humanized antibody, an animal antibody (e.g. camelid antibody), chimeric antibodies, as well as portions, fragments, regions, peptides and derivatives thereof (provided by any known technique, such as, but not limited to, enzymatic cleavage, peptide synthesis, or recombinant techniques), such as, for example, immunoglobulin devoid of light chains, Fab, Fab′, F (ab′)2, Fv, scFv, antibody fragment, diabody, Fd, CDR regions, or any portion or peptide sequence of the antibody that is capable of binding antigen or epitope. In one embodiment, the functional part is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab′)2 fragment.
  • An antibody or functional part is said to be “capable of binding” a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody. Antibody fragments or portions may lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. Examples of antibody may be produced from intact antibodies using methods well known in the art, for example by proteolytic cleavage with enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)2 fragments). Portions of antibodies may be made by any of the above methods, or may be made by expressing a portion of the recombinant molecule. For example, the CDR region(s) of a recombinant antibody may be isolated and subcloned into an appropriate expression vector.
  • In one embodiment, an antibody or functional part is a human antibody. The use of human antibodies for human therapy may diminish the chance of side effects due to an immunological reaction in a human individual against nonhuman sequences. In another embodiment, the antibody or functional part is humanized. In another embodiment, an antibody or functional part is a chimeric antibody. This way, sequences of interest, such as for instance a binding site of interest, can be included into an antibody or functional part.
  • In one embodiment, the antibody may have an IgG, IgA, IgM, or IgE isotype. In one embodiment, the antibody is an IgG.
  • B. Radiation Therapy for Use in Methods of Treatment
  • Radiation therapy, also known as high-dose ionizing irradiation, is a component of the present therapeutic approach.
  • In one mode, the radiation therapy is fractionated radiation therapy. In one embodiment, the fractionated radiation therapy comprises from 2 to 7 fractions. In another embodiment, the fractionated radiation therapy comprises from 3 to 6 fractions. In another embodiment, the fractionated radiation therapy comprises from 4 to 5 fractions. In one mode, the fractionated radiation therapy comprises 2, 3, 4, 5, 6, or 7 fractions. In one embodiment, the fractionated radiation therapy comprises 5 fractions.
  • In one mode, the radiation therapy fractions are administered in sequential days. In one mode, radiation therapy may include more than one dose on a day and/or doses on sequential days. In one mode, the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5. In another mode, the radiation therapy comprises about 10 Gy in 5 fractions (i.e., 2 Gy on each of 5 days).
  • Other fractionation schedules may be employed including accelerated fractionation (treatment given in larger daily or weekly doses to reduce the number of weeks of treatment), hyperfractionation (smaller doses of radiation given more than once a day), or hypofractionation (larger doses given once a day or less often to reduce the number of treatments).
  • The radiation therapy may be x-rays, gamma rays, or charged particles. The radiation therapy may be external-beam radiation therapy or internal radiation therapy (also called brachytherapy). Systemic radiation therapy, using radioactive substances, such as radioactive iodine, may also be employed.
  • External-beam radiation therapy includes 3D conformational radiation therapy, intensity-modulated radiation therapy, image-guided radiation therapy, tomotherapy, stereotactic radiosurgery, proton therapy, or other charged particle beams.
  • C. Cancers for Treatment
  • The present methods may be used to treat a variety of types of cancer. In one aspect, the method may be used to treat melanoma, colorectal cancer, or breast cancer. In one embodiment, the breast cancer is triple negative breast cancer.
  • In one embodiment, the cancer is cancer is adrenocortical tumors, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, chest cancer, colon cancer, colorectal cancer, endometrial cancer, epidermoid carcinoma, esophageal cancer, eye cancer, glioblastoma, glioma, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor, gestational trophoblastic disease, head and neck, Hodgkin disease, Kaposi sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, leukemia, liver cancer (such as hepatocellular carcinoma), lung cancer (including non-small cell, small cell, and lung carcinoid tumors), lymph node cancer, lymphoma, lymphoma of the skin, melanoma, mesothelioma, mouth cancer, multiple myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, pediatric malignancies, rectal cancer, retinoblastoma, rhabdomyosarcoma, salivary gland, sarcoma, skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymus cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, or vulvar cancers.
  • Reference will now be made in detail to the present exemplary embodiments, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. Other embodiments will be apparent to those skilled in the art from consideration of the specification and practice disclosed herein. The embodiments are further explained in the following examples. These examples do not limit the scope of the claims, but merely serve to clarify certain embodiments. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit being indicated by the following claims.
    • EXAMPLES Example 1 Methods
  • A) Mice and Cell Lines
  • BALB/c and C57Bl/6 mice were obtained from Harlan, U.K. All animal experiments were approved by a local ethical committee and performed under a United Kingdom Home Office license. CT26 murine colon carcinoma cells (ATCC) and 4434 cells isolated from BRafV600E p16−/− mice (Richard Marias, Cancer Research UK, Manchester Institute) were maintained in DMEM, and 4T1 triple negative breast cancers (ATCC) maintained in RPMI-1640, supplemented with 10% FCS, 1% L-glutamine (Invitrogen, U.K.). All cell lines were routinely screened to confirm the absence of Mycoplasma contamination.
  • B) Tumor Therapy
  • Mice were inoculated sub-cutaneously (s.c.) with either 5×105 CT26, 1×105 4T1 or 5×106 4434 cells. Irradiations were performed 7-10 days after inoculation (when tumors were at least 100 mm3) using a Pantak HF-320 320 kV x-ray unit (Gulmay Medical, U.K.). The machine was operated at 300 kV, 9.2 mA, with filtration fitted in the x-ray beam to give a radiation quality of 2.3 mm Cu half-value layer. Mice were positioned at a distance of 350 mm from the x-ray focus, where the dose rate was 0.80 Gy/min. Administration of αPD-1 (clone RMPI-14), αPD-L1 (clone 10F.9G2) (both Biolegend) or isotype control mAb (IgG2a and IgG2b respectively) commenced on day 1 of the fractionated RT cycle (unless otherwise stated) and was administered intra-peritoneally (i.p.) 3qw for up to 3 weeks at a dose of 10 mg/kg in a dose volume of 100 μl/10 g in PBS. For cellular and cytokine depletion experiments mice received either αCD8 mAb; clone YTS169 (a gift from M. Glennie, Southampton University), αCD4 mAb; clone GK1.5 (Biolegend), αAsialo-GM1 (Wako Chemicals) or αIFNγ; clone XMG1.2 (BioXcell). Peripheral blood was sampled during therapy to confirm cellular depletion. For tumor rechallenge experiments, long-term surviving (LTS) mice were implanted contralaterally with tumor cells a minimum of 100 days after previous tumor implantation. Additional control mice were also implanted to confirm tumor growth. Experimental groups contained at least 5 mice/group and are representative at least 2 independent experiments.
  • C) Measurement of Cytokine Production by CD8+ T Cells Isolated from Long-Term Surviving Mice
  • For in vitro stimulation 3.5×106 splenocytes from either LTS or control mice were cultured for 5 days in RPMI-1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 1% L-glutamine, 50 μM 2-ME and 10 IU/ml human recombinant IL-2 in the presence of either 1×106 tumor cells irradiated with 50 Gy or 1 μmol/ml of the H2-Ld restricted peptides SPSYVYHQF (SEQ ID NO: 91) (AH1)/TPHPARIGL (SEQ ID NO: 92) (β-galactosidase) (Anaspec, U.K.). Experimental groups contained 3-5 mice and are representative of 2 independent experiments. After 5 days in culture, cells were restimulated at a 1:1 ratio with 50 Gy irradiated tumor cells for 16 hours in the presence of 3 ug/ml Brefeldin A (BD Pharmingen, U.K.) and 100 IU/ml human recombinant IL-2 (Chiron, NL). For FACS analysis, cells were washed and incubated with rat anti-CD16/32 (eBioscience, U.K.) to block non-specific binding and then stained with a FITC conjugated anti-CD8α mAb (eBioscience, U.K.). Cells were then fixed/permeabilized and stained for expression of IFNγ using an APC conjugated mAb (eBioscience, U.K.).
  • D) Tumor and Immune Cell Phenotyping by Flow Cytomtery
  • To obtain single cell suspensions, tumors were processed using a gentleMacs dissociator and a murine tumor dissociation kit (Miltenyi Biotec, U.K.). For analysis, non-specific binding was blocked as described above and expression of CD4, CD8 (BD Biosciences, UK), CD45, NKP46, PD-1 and PD-L1 examined by multi-parameter flow cytometry (all eBioscience unless otherwise stated).
  • E) In Vitro Co-Cultures
  • Tumor cells were cultured in the presence of 20 ng/ml IFNγ and/or TNFα for 24 hours prior to evaluation of PD-L1 expression by flow cytometry as described above. For co-culture assay either resting or activated splenocytes (treated with PBS or phorbol 12-Myristate 13-Acetate and Ionomycin cell stimulation cocktail respectively, (eBioscience, UK)) were co-cultured at a 1:1 ratio with tumor cells and tumor cell expression of PD-L1 determined as described above. Silencing of IFNγR1 expression was achieved by lentiviral transduction of cells with ShRNA (cells were also transduced with non-targeting ShRNA as controls) (Thermo Scientific, UK). Measurement of splenocyte cytokine production (IFNγ and TNFα) was measured by intracellular flow cytometry as described above.
    • Example 2 Blockade of PD-1 or PD-L1 Enhances the Therapeutic Efficacy of RT
  • Radiation therapy has been shown to modulate the immunogenicity of tumor cells but is rarely able to generate durable therapeutic responses that lead to systemic anti-tumor immunity alone. We show that low doses of local fractionated dose RT delivered as about 10 Gy in 5 fractions leads to increased tumor cell expression of PD-L1 with elevated expression evident 1, 3 and 5 days after the last dose of RT when compared to time-matched, non-treated (NT) mice (FIGS. 1A and B). This RT-mediated increase in tumor cell PD-L1 expression peaks at 72 hours after the last dose of RT and although it declines significantly by 7 days post RT (when compared to expression at days 1 and 3; P<0.05 and P<0.01 respectively, Mann-Whitney test) remains elevated when compared to NT mice (P<0.05, Mann-Whitney test).
  • Given these observations we hypothesized that the immune response generated following RT may be limited through the PD-1/PD-L1 axis. Local RT delivered as about 10 Gy in 5 daily fractions was found to significantly improve survival in mice bearing established CT26 tumors when compared to NT controls (FIGS. 1C and D; P<0.05 Log-rank; Mantel-Cox test). Our data demonstrate that this RT-mediated local tumor control can be substantially improved through combination with either αPD-L1 mAb or αPD-1 mAb (FIGS. 1C and D; P<0.001 Log-rank; Mantel-Cox test). Combined therapy led to a synergistic anti-tumor response which was curative in 66% and 80% of mice that received RT in combination with αPD-L1 mAb or αPD-1 mAb respectively. In contrast to combination with RT, monotherapy with either αPD-L1 mAb or αPD-1 mAb did not significantly improve survival (FIGS. 1C and D; P>0.05 Log-rank; Mantel-Cox test). Further, no significant benefit was observed when mice received RT in combination with both αPD-1 and αPD-L1 mAb vs. combination with either mAb alone (FIG. 7).
  • Blockade of PD-L1 also improved response to RT in mice bearing established 4T1 tumors where combined therapy significantly reduced tumor burden by 38% when compared to RT alone (FIG. 1E; 10 days post start of therapy; 184.3±13.5 mm2 vs. 292.8±14.3 mm2 respectively, P<0.01 Mann-Whitney test) and significantly improved survival (P<0.001 Log-rank; Mantel-Cox test; data not shown). Similar results were also observed in mice bearing established 4434 melanomas (FIG. 1F). Combination therapy with local RT and mAbs targeting either PD-1 or PD-L1 was well tolerated in both BALB/c and C57Bl/6 mice (FIGS. 8A and B). These preclinical data clearly demonstrate the potential to improve outcome following low dose fractionated RT of established solid tumors through blockade of the PD-1/PD-L1 axis.
    • Example 3 NK Cells Contribute to Local Tumor Control Following Combination Therapy but Long-Term Survival is Dependent on CD8+ T Cells
  • We next investigated the mechanisms underlying the long-term tumor control observed following combination RT and αPD-L1 mAb therapy. Initially colony forming assays were used to confirm that αPD-1 and αPD-L1 mAb were not acting as radiation sensitizers through direct interaction with tumor cells (FIG. 9A-C). Using depleting antibodies, we next explored the role of effector T cells and NK cells in mediating anti-tumor activity following RT/αPD-L1 mAb combination therapy. Our data demonstrate that as early as 7 days after the start of a 5 day fractionated RT cycle (with αPD-L1 mAb therapy commencing on day 1 of the RT cycle) reduced tumor burden is evident in mice following combination therapy when compared to NT mice (207.5±29.2 mm2 vs. 409.4±86.88 mm2 respectively; P=0.067, Mann-Whitney U test) (FIG. 2A). However, this statistical trend to reduced volume was lost following depletion of either CD8+ T cells or NK cells, where tumor volumes were not significantly different from those in NT cohorts (P=0.52 and P=0.70 respectively, Mann-Whitney U test) but significantly larger than mice that received combination therapy without immune cell depletion (P<0.01; combined therapy vs. CD8 depletion, and P<0.05; combined therapy vs. NK cell depletion, Mann-Whitney U test). By day 11 post treatment, combination therapy significantly reduces tumor burden when compared to NT controls (P<0.001, Mann-Whitney U test). Whilst the depletion of either CD8+ T cells or NK cells at this time point reduces the efficacy of combination therapy (P<0.001 and P<0.05 respectively, Mann-Whitney U test), the relative contribution of CD8+ T cells and NK cells becomes more evident with significantly reduced tumor control in CD8 vs. NK cell depleted mice (P<0.05, Mann-Whitney U test). Our data also reveal that the depletion of CD4+ T cells improved local tumor control following combination therapy (153.2±27.0 mm2 vs. 72.7±17.3mm2 respectively; P<0.05, Mann-Whitney U test).
  • In contrast to early tumor control following combination RT/αPD-L1 mAb therapy, long term survival (LTS) was not impacted by the depletion of NK cells (70% LTS mice following treatment with RT/αPD-L1 vs. 77.8% following combination therapy with NK cell depletion) (FIG. 2B). The depletion of CD4+ T lymphocytes increased the frequency of LTS mice from 70% to 87.5% (combination vs. combination+CD4 depletion) but this did not achieve significance (P>0.05 Log-rank; Mantel-Cox test). However, the depletion of CD8+ T cells completely abrogated the therapeutic efficacy of combination RT/αPD-L1 mAb therapy (P<0.001 Log-rank; Mantel-Cox test). Depletion of immune cell populations was confirmed by flow cytometry on peripheral blood samples (FIG. 2C). These data suggest that whilst NK cells may exert some local tumor control this does not impact overall survival and while CD4+ T cells are dispensable or even capable of suppressing responses, CD8+ T cells appear to mediate effective long term tumor control following treatment with RT and αPD-L1 mAb.
    • Example 4 Treatment with αPD-L1 mAb and RT Generates Protective Tumor Antigen-Specific Memory T Cell Responses
  • We next investigated whether immunological memory was generated following treatment with RT and αPD-L1 mAb. We show that LTS mice originally treated with RT and αPD-L1 mAb were able to completely reject tumors following contralateral rechallenge (FIG. 3A). To quantify this memory response splenocytes were harvested from LTS mice that had greater than 100 days of disease free survival and the capacity of CD8+ T cells to produce IFNγ following co-culture with peptide derived from a CT26 tumor associated antigen (AH1: SPSYVYHQF (SEQ ID NO: 91)), control peptide (β-galactosidase: TPHARIGL (SEQ ID NO: 93)) or with irradiated CT26 cells was assessed (FIG. 3B and C). Our data reveal that LTS mice were endowed with a significantly greater frequency of IFNγ-producing CD8+ T lymphocytes following co-culture with AH1 peptide than naïve mice (6.6%±0.8 vs 2.3%±0.2 respectively; P<0.05, Mann-Whitney test). A similar response was observed following co-culture of splenocytes with CT26 cells. Comparison of peptide and tumor cell co-cultures revealed that the frequency of memory CD8+ T cells was ˜3 fold lower in LTS mice following co-culture with tumor cells than with AH1 peptide and may reflect tumor cell-mediated suppression of T cell activation. Taken together these data demonstrate that RT when combined with blockade of the PD-1/PD-L1 axis in mouse models can generate protective immunological memory in long-term survivors.
    • Example 5 Fractionated RT Leads to CD8+ T Cell Dependent Adaptive Upregulation of Tumor Cell PD-L1 Expression
  • Initially we confirmed that treatment of tumor cells with a range of RT doses in vitro did not have any direct impact on expression of PD-L1 (FIG. 4A). To identify which cellular populations within the tumor microenvironment were responsible for modulating tumor cell expression of PD-L1 mice received a fractionated RT cycle in combination with CD8, CD4 or NK cell depleting antibodies. Our data reveal that the depletion of CD8+ T cells but not NK cells completely abrogates the RT-mediated upregulation of PD-L1 on tumor cells (FIGS. 4B and C). Interestingly, the depletion of CD4+ T cells was found to further augment RT-mediated upregulation of PD-L1 on tumor cells (˜2 fold compared to treatment with RT alone).
    • Example 6 Adaptive Upregulation of PD-L1 by Tumor Cells Following Fractionated RT is IFNγ Dependent
  • Given the clinical correlation between IFNγ in the tumor microenvironment and PD-L1 expression (16) and the impact of TNFα on this response (22) we evaluated the impact of these cytokines on PD-L1 in our cell lines. Co-culture of tumor cells with recombinant IFNγleads to a significant 20 fold increase in cell surface expression of PD-L1 in vitro (FIG. 5A). Furthermore, whilst addition of recombinant TNFα alone has no impact on tumor cell expression of PD-L1, a cocktail of both IFNγ and TNFα can further augment tumor cell PD-L1 expression (˜2 fold) when compared to expression with IFNγ alone (FIG. 5A). We show that silencing of IFN-γ-receptor 1 (IFNγR1) on CT26 tumor cells using ShRNA completely abrogates the upregulation of PD-L1 following co-culture with either recombinant IFNγ or both IFNγ and TNFα (FIG. 5A).
  • To establish whether activated immune cells could lead to an adaptive change in tumor cell expression of PD-L1 through the production of IFNγ and TNFα, WT CT26 cells and those transduced with either non-targeting ShRNA (NTC ShRNA) and IFNγR1 ShRNA were co-cultured with isolated resting (PBS-treated) and activated (phorbol 12-myristate 13-acetate (PMA) and ionomycin-treated) splenocytes (FIGS. 5B and C). Importantly, these experiments demonstrate that activated immune cells can elevate tumor cell PD-L1 expression at physiologically relevant concentrations of IFNγ and TNFα, in an IFNγR1-dependent manner.
  • To confirm the role of IFNγ on tumor cell expression of PD-L1 in response to RT in vivo, mice received RT in combination with αIFNγ blocking antibody (or isotype control). IFNγ blockade reduced tumor cell expression of PD-L1 by 2.6 fold in NT mice to the level observed on CT26 cells cultured in vitro; suggesting adaptive upregulation of PD-L1 occurs following implantation of tumor (FIGS. 5D and E). However, the significant upregulation of PD-L1 observed following RT (2.4 fold compared to NT control) was completely abrogated by IFNγ blockade confirming this as the driver of adaptive tumor cell expression of PD-L1 following RT treatment.
    • Example 7 Concomitant Scheduling of αPD-L1 mAb and RT Generates an Effective Anti-Tumor Immune Response
  • We evaluated 3 distinct combination schedules where mice bearing established CT26 tumors received a fractionated RT cycle of about 10 Gy in 5 fractions with administration of αPD-L1 mAb commencing either on day 1 of the fractionated RT cycle (schedule A), day 5 of the cycle (schedule B) or 7 days after completion of RT (schedule C) (FIG. 6A). No significant difference in overall survival was found between schedule A and B with LTS of 60% and 57 respectively (P>0.05 Log-rank; Mantel-Cox test) (FIG. 6B and FIG. 10A). In contrast, sequential treatment with RT followed 7 days later by αPD-L1 mAb (Schedule C) was completely ineffective at enhancing overall survival when compared to RT alone (median survival of 30 days vs. 35 days respectively; P>0.05 Log-rank; Mantel-Cox test) despite similar tumor burden across groups (FIGS. 10B and C).
  • Analysis of tumor infiltrating CD4+ and CD8+ T cells 24 hours after the last dose of RT reveal increased expression of PD-1 when compared to time-matched NT controls (P<0.05, Mann-Whitney test) (FIG. 6C). In contrast, by 7 days post RT no change in PD-1 expression was evident on CD4+ T cells and was found to be significantly decreased on CD8+ T cells when compared to time-matched NT controls (P<0.05, Mann-Whitney test) (FIG. 6D). Expression of PD-1 was consistently found to be higher on tumor infiltrating CD8+ than CD4+ T cells (FIGS. 6C and D). We next compared activity following an acute vs. extended αPD-L1 mAb dosing protocol where mice received either 3 doses of mAb concurrent with RT or the same with dosing extended (3qw) for an additional 2 weeks. No additional benefit was observed with extended αPD-L1 mAb administration (FIG. 11).
  • Taken together these data demonstrate that treatment with low dose fractionated RT leads to an acute increase in PD-1 expression on T cells and that sequential therapy where blockade of the PD-1/PD-L1 signalling axis is delayed until completion of an RT cycle may be ineffective potentially due to deletion or anergy of tumor-reactive CD8+ T cells.
    • Example 8 Discussion of Preceding Examples
  • Low doses of fractionated RT leads to upregulation of PD-L1 expression on tumor cells secondary to CD8+ T cell production of IFNγ. In mouse models of melanoma, colorectal and breast cancer we demonstrate that the activity of RT can be enhanced through combination with αPD-L1 mAb, leading to the generation of immunological memory in long-term surviving mice which is capable of protecting against tumor recurrence. Furthermore, our data reveal that dose scheduling may affect outcomes, with concurrent but not sequential therapy effective at improving local tumor control and survival.
  • This is the first preclinical study to demonstrate that fractionated RT leads to increased tumor cell expression of PD-L1 through CD8+ T cell production of IFNγ. Here, tumor cell expression of PD-L1 may act as a biomarker of a local anti-tumor response, suggesting that local RT may be sufficient to prime CD8+ T cell responses. However, whilst treatment with RT alone was unable to generate durable anti-cancer immunity, activity was found to be enhanced through mAb-mediated blockade of either PD-1 or PD-L1 suggesting that signalling through this axis may limit the immune response to RT. We saw no significant differences in overall survival between RT delivered in combination with either αPD-1 or αPD-L1, or a combination of both mAb. Given this observation it seems likely that the activity of these mAbs when delivered in combination with RT is through blockade of PD-1/PD-L1 signalling, and not mediated through the PD-L1/CD80 or PD-1/PD-L2 axes, although further experiments are needed to confirm this.
  • Our preclinical data reveal that the depletion of NK cells reduced local tumor control at early time points (up to 11 days post completion of RT) but did not impact on overall survival. In addition, the depletion of NK cells did not impact tumor cell expression of PD-L1 following RT suggesting their limited contribution to local IFNγ production. In contrast, whilst depletion of CD4+ T cells did not impact survival following combination therapy, substantial increases in tumor cell expression of PD-L1 post RT was observed. The depletion of CD4+ T cells impacts both helper T cell and Treg populations. Although further studies are needed to delineate the relative contributions of these sub-populations of CD4+ T cells we can speculate that CD4+ helper T cells may be dispensable for the generation of effective CD8+ T cell responses post RT/PD-L1 mAb therapy in our model and that either helper T cells, or more likely Treg, may be actively suppressing IFNγ production in the local tumor milieu. Therefore, the therapeutic potential to enhance anti-tumor responses by Treg depletion may be at least in part attenuated through enhanced tumor cell expression of PD-L1.
  • PD-L1 expression can be modulated by a number of cytokines including type-1 and 2 IFN, TNFα and TGFβ (16, 22, 30-32). We show that tumor cell expression of PD-L1 can be enhanced following co-culture with IFNγ and that addition of TNFα can further augment this response. However, blockade of IFNγR1 or in vivo depletion of IFNγ demonstrates dependence on IFNγ mediated signalling for upregulation of PD-L1, with TNFα alone incapable of modulating tumor cell PD-L1 expression. Interestingly, in vivo depletion of IFNγ reduces PD-L1 expression on syngeneic tumor cells, matching the expression profile of tumor cells in vitro. This suggests that the local tumor microenvironment in the absence of therapeutic intervention may foster immunologically driven tumor adaptation which may support tumor development. Similarly, in human melanocytic lesions expression of PD-L1 has been shown to co-localize with areas of CD8+ T cell infiltration and is postulated to represent an adaptive mechanism of immune escape (16). However, in our preclinical mouse models monotherapy with mAbs targeting PD-1/PD-L1 only demonstrates modest activity, suggesting that targeting this axis alone may be unlikely to bring about durable anti-tumor immune responses in all settings and underscores the requirement for a combinatorial approach.
  • In contrast to the use of a single 12 Gy dose (30), our results demonstrate that upregulation of PD-L1 occurs at much lower biologically effective doses involving delivery of fractionated RT using about 10 Gy in 5 daily fractions. This is an important finding given that this dose per fraction is more commonly used in routine clinical practice. Several studies have assessed the impact of RT dose fractionation; comparing single ablative doses, hypofractionated and fractionated RT, on the generation of anti-tumor immune responses and on the tumor microenvironment (4, 5, 25, 26, 33, 34). However, the results of these studies are equivocal and optimal RT delivery and the impact of RT dose fractionation on tumor cell expression of PD-L1 requires further investigation.
  • Previously, no research has addressed the impact of sequencing on the activity of RT and αPD-L1 mAb therapy. This is especially pertinent given the predisposition to adopting a sequenced combination regimen in the clinic as a strategy to maximize tolerability. We show that only blockade of PD-L1 at the time of RT delivery can enhance the therapeutic response in mouse models, with therapy 7 days after completion of RT no better than treatment with RT alone. In addition, our data reveal that PD-L1 expression is elevated by 24 hours after completion of a fractionated RT cycle and remains elevated for at least 7 days post completion. Moreover, we found elevated PD-1 expression on tumor infiltrating CD4+ and CD8+ T cells 24 hours post RT when compared to control cohorts. Expression of PD-1 was found to be consistently higher on CD8+ vs. CD4+ T cells. Taken together these data suggest that local fractionated RT can prime anti-tumor CD8+ T cell responses but that these may be attenuated by signalling through the PD-1/PD-L1 axis and early inhibition of this axis may generate durable effective anti-tumor responses. Further, the requirement for chronic vs. acute blockade of the PD-1/PD-L1 axis when combined with RT is unclear. We observed no difference in survival when αPD-L1 mAb was administered 3qw over 1 week concurrent with RT delivery vs. an extended schedule of up to 3 weeks. These data suggest that combination approaches with RT may permit a reduction in the duration of αPD-1/PD-L1 mAb therapy required to achieve therapeutic anti-tumor immune responses. Together these data have important implications for clinical trial design.
  • In summary, this study demonstrates that treatment with fractionated RT leads to upregulation of tumor cell expression of PD-L1 and that blockade of the PD-1/PD-L1 axis can enhance the immune response to fractionated RT in multiple syngeneic mouse models of cancer. Our data suggest that dose scheduling of αPD-L1 mAb with RT may generate therapeutic immune responses with the capacity to reduce tumor burden and improve survival. This therapeutic combination may be a promising approach for the treatment of many solid malignancies where RT is commonly used and translation to early phase clinical trial is clearly warranted.
    • Example 9 Treatment Protocols
  • Patient A has colorectal cancer. In week 1, patient A receives an effective amount of radiation therapy in five fractions. In week 1, patient A also receives a therapeutic dose of MEDI4736 on day 1, day 3, and day 5. Patient A repeats this schedule for weeks 2, 3, 4, and 5.
  • Patient B has breast cancer. In week 1, patient B receives an effective amount of radiation therapy. In week 1, patient B also receives a therapeutic dose of MEDI4736 on day 5. Patient repeats this schedule for weeks 3, 5, and 7.
    • Example 10 Certain Embodiments
  • The following items provide certain embodiments disclosed herein.
  • Item 1. A method of treating cancer in a patient comprising
      • a. administering at least one dose of radiation therapy; and
      • b. administering at least one PD-1 and/or PD-L1 antagonist,
        • wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
  • Item 2. The method of item 1, wherein the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof.
  • Item 3. The method of any one of items 1-2, wherein the dose of radiation therapy is about 11 Gy or lower.
  • Item 4. The method of item 3, wherein the dose of radiation therapy is about 10 Gy or lower.
  • Item 5. The method of any one of items 1-4,wherein the radiation therapy is fractionated radiation therapy.
  • Item 6. The method of item 5, wherein the fractionated radiation therapy comprises from 2 to 7 fractions.
  • Item 7. The method of item 6, wherein the fractionated radiation therapy comprises 5 fractions.
  • Item 8. The method of any one of items 5-7, wherein the radiation therapy fractions are administered in sequential days.
  • Item 9. The method of any one of items 5-8, wherein the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5.
  • Item 10. The method of any one of items 7-9, wherein the radiation therapy comprises about 10 Gy in 5 fractions.
  • Item 11. The method of any one of items 1-10, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 1.
  • Item 12. The method of any one of items 1-11, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 5.
  • Item 13. The method of any one of items 1-12, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
  • Item 14. The method of any one of items 1-13, wherein the at least one PD-1 and/or PD-L1 antagonist is administered 3 times a week.
  • Item 15. The method of any one of items 1-14, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
  • Item 16. The method of any one of items 1-15, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.
  • Item 17. The method of any one of items 1-16, wherein the cancer is melanoma, colorectal cancer, or breast cancer.
  • Item 18. The method of any one of items 1-17, wherein more than one treatment cycle is performed.
  • Item 19. The method of item 18, wherein from 2-8 treatment cycles are performed.
  • Item 20. The method of any one of items 18-19, wherein the treatment cycles are weekly.
  • Item 21. The method of any one of items 18-19, wherein the treatment cycles are every other week.
    • REFERENCES
  • 1. D. Verellen et al., Innovations in image-guided radiotherapy. Nat Rev Cancer 7, 949-960 (2007).
  • 2. L. J. Lee et al., Innovations in radiation therapy (RT) for breast cancer. Breast 18 Suppl 3, S103-111 (2009).
  • 3. E. Kapiteijn et al., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345, 638-646 (2001).
  • 4. Y. Lee et al., Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-595 (2009).
  • 5. A. A. Lugade et al., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174, 7516-7523 (2005).
  • 6. L. Apetoh et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-1059 (2007).
  • 7. S. J. Gardai et al., Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
  • 8. F. Ghiringhelli et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178 (2009).
  • 9. Y. Ma et al., Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729-741 (2013).
  • 10. J. Honeychurch et al., Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leuk Lymphoma 54, 2008-2015 (2013).
  • 11. B. Cummings et al., Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 85, 7-16 (2007).
  • 12. H. Dong et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8, 793-800 (2002).
  • 13. G. J. Freeman et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027-1034 (2000).
  • 14. M. J. Butte et al., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007).
  • 15. S. Spranger et al., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5, 200ra116 (2013).
  • 16. J. M. Taube et al., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4, 127ra137 (2012).
  • 17. M. Sznol et al., Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19, 1021-1034 (2013).
  • 18. J. R. Brahmer et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28, 3167-3175 (2010).
  • 19. J. R. Brahmer et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366, 2455-2465 (2012).
  • 20. O. Hamid et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369, 134-144 (2013).
  • 21. E. J. Lipson et al., Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19, 462-468 (2013).
  • 22. A. Kondo et al., Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 116, 1124-1131 (2010).
  • 23. S. L. Topalian et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454 (2012).
  • 24. S. L. Topalian et al., Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol, (2014).
  • 25. M. Z. Dewan et al., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15, 5379-5388 (2009).
  • 26. S. J. Dovedi et al., Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 121, 251-259 (2013).
  • 27. J. Honeychurch et al., Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102, 1449-1457 (2003).
  • 28. B. C. Burnette et al., The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71, 2488-2496 (2011).
  • 29. J. Y. Kim et al., Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 38, 474-484 (2006).
  • 30. L. Deng et al., Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124, 687-695 (2014).
  • 31. J. N. Ou et al., TNF-alpha and TGF-beta counter-regulate PD-L1expression on monocytes in systemic lupus erythematosus. Sci Rep 2, 295 (2012).
  • 32. S. Terawaki et al., IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186, 2772-2779 (2011).
  • 33. D. Schaue et al., Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83, 1306-1310 (2012).
    • EQUIVALENTS
  • The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the embodiments. The foregoing description and Examples detail certain embodiments and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the embodiments may be practiced in many ways and the claims include any equivalents thereof.
  • As used herein, the term about refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term about generally refers to a range of numerical values (e.g., +/−5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term about may include numerical values that are rounded to the nearest significant figure.

Claims (55)

What is claimed is:
1-20. (canceled)
21. A method of treating lung cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
22. The method of claim 21, where in the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
23. The method of claim 21, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
24. The method of claim 23, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
25. The method of claim 21, wherein the radiation therapy fractions are administered on sequential days.
26. The method of claim 21, wherein the at least one PD-1 and/or PD- antagonist is administered on day 1.
27. The method of claim 21, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
28. A method of treating bladder cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
29. The method of claim 28, where in the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
30. The method of claim 28, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
31. The method of claim 30, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
32. The method of claim 28, wherein the radiation therapy fractions are administered on sequential days.
33. The method of claim 28, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 1.
34. The method of claim 28, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
35. A method of treating head and neck cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
36. The method of claim 35, where in the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
37. The method of claim 35, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
38. The method of claim 37, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
39. The method of claim 35, wherein the radiation therapy fractions are administered on sequential days.
40. The method of claim 35, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 1.
41. The method of claim 35, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times.
42. A method of treating lung cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antibody or functional part thereof, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
43. The method of claim 42, where in the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
44. The method of claim 42, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
45. The method of claim 44, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
46. The method of claim 42, wherein the radiation therapy fractions are administered on sequential days.
47. The method of claim 42, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on day 1.
48. The method of claim 42, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered multiple times.
49. The method of claim 42, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
50. The method of claim 42, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab.
51. The method of claim 42, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is nivolumab.
52. The method of claim 42, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is MPDL3280A.
53. A method of treating bladder cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antibody or functional part thereof, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
54. The method of claim 53, where in the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
55. The method of claim 53, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
56. The method of claim 55, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
57. The method of claim 53, wherein the radiation therapy fractions are administered on sequential days.
58. The method of claim 53, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on day 1.
59. The method of claim 53, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered multiple times.
60. The method of claim 53, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
61. The method of claim 53, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab.
62. The method of claim 53, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is nivolumab.
63. The method of claim 53, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is MPDL3280A.
64. A method of treating head and neck cancer in a patient comprising:
a. administering to the patient radiation therapy that includes a fraction of fractionated radiation therapy; and
b. administering to the patient at least one PD-1 and/or PD-L1 antibody or functional part thereof, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 42 days later, wherein the fraction is 2.2 Gy or lower.
65. The method of claim 64, where in the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on the same day as the last fraction of radiation therapy or up to and including 14 days later.
66. The method of claim 64, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower.
67. The method of claim 66, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower.
68. The method of claim 64, wherein the radiation therapy fractions are administered on sequential days.
69. The method of claim 64, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered on day 1.
70. The method of claim 64, wherein the at least one PD-1 and/or PD-L1 antibody or functional part thereof is administered multiple times.
71. The method of claim 64, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.
72. The method of claim 64, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab.
73. The method of claim 64, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is nivolumab.
74. The method of claim 64, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is MPDL3280A.
US16/121,867 2014-06-17 2018-09-05 Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy Abandoned US20190192655A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/121,867 US20190192655A1 (en) 2014-06-17 2018-09-05 Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013157P 2014-06-17 2014-06-17
US14/740,876 US10092645B2 (en) 2014-06-17 2015-06-16 Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US16/121,867 US20190192655A1 (en) 2014-06-17 2018-09-05 Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/740,876 Continuation US10092645B2 (en) 2014-06-17 2015-06-16 Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Publications (1)

Publication Number Publication Date
US20190192655A1 true US20190192655A1 (en) 2019-06-27

Family

ID=53498965

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/740,876 Active US10092645B2 (en) 2014-06-17 2015-06-16 Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US16/121,867 Abandoned US20190192655A1 (en) 2014-06-17 2018-09-05 Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/740,876 Active US10092645B2 (en) 2014-06-17 2015-06-16 Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Country Status (19)

Country Link
US (2) US10092645B2 (en)
EP (2) EP3157629B1 (en)
JP (4) JP6877147B2 (en)
KR (3) KR102592781B1 (en)
CN (1) CN107073107A (en)
AU (3) AU2015276173B2 (en)
BR (1) BR112016028964A2 (en)
CA (1) CA2950046C (en)
DK (1) DK3157629T3 (en)
ES (1) ES2933603T3 (en)
HU (1) HUE060689T2 (en)
IL (1) IL249133B (en)
MX (3) MX2016015346A (en)
PL (1) PL3157629T3 (en)
PT (1) PT3157629T (en)
RU (1) RU2711408C2 (en)
SG (2) SG10202108654PA (en)
TW (2) TWI751101B (en)
WO (1) WO2015193352A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446401B2 (en) 2018-12-03 2022-09-20 Fusion Pharmaceuticals Inc. Actinium-225 and checkpoint inhibitor combination therapy

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240056664A (en) * 2013-09-11 2024-04-30 메디뮨 리미티드 Anti-b7-h1 antibodies for treating tumors
UA119659C2 (en) 2013-12-12 2019-07-25 Шанхай Хенжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JP6829193B2 (en) * 2014-10-27 2021-02-10 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ Use of CCR5 antagonists in monotherapy or combination therapy to treat cancer
TWI609687B (en) 2015-04-14 2018-01-01 美國禮來大藥廠 Targeted treatment of leiomyosarcoma
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
HRP20231156T1 (en) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR102418766B1 (en) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 Combination Therapy of Notch and a PI3K/mTOR Inhibitor for Use in the Treatment of Cancer
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
CN109379889A (en) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 Pass through the immune activation or immunoregulatory immunotherapy for cancer via GLOBO series antigen
AR108377A1 (en) * 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
TW202408578A (en) * 2016-05-13 2024-03-01 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
BR112018073673A2 (en) * 2016-05-20 2019-02-26 Eli Lilly And Company combination therapy with notch and pd-1 or pd-l1 inhibitors
CN110072545A (en) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 Immunogenicity/therapeutic glycan pool object and application thereof
CN110062767B (en) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 Human antibodies, pharmaceutical compositions and methods
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP3532494A4 (en) * 2016-10-26 2020-06-03 The Children's Medical Center Corporation Methods and compositions for modulaton of transforming growth factor beta-regulated functions
US11000601B2 (en) 2016-11-21 2021-05-11 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
KR102603681B1 (en) 2016-12-07 2023-11-17 아게누스 인코포레이티드 Antibodies and methods of using them
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
MA47604A (en) 2017-02-21 2020-01-01 Regeneron Pharma ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2019094265A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Pd1 polypeptide binding molecules
EP3710477A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137
KR20210005007A (en) * 2018-03-22 2021-01-13 서피스 온콜로지, 인크. Anti-IL-27 antibodies and uses thereof
JP7368453B2 (en) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド High affinity antibodies against PD-1 and LAG-3 and bispecific binding proteins made therefrom
US10949272B2 (en) * 2018-06-14 2021-03-16 Microsoft Technology Licensing, Llc Inter-application context seeding
KR102167539B1 (en) * 2018-12-28 2020-10-20 한국원자력의학원 Method for providing information for predicting the prognosis of radiation therapy, comprising step of measuring the expression level of immune checkpoint of cancer cell which is changed during the radiation therapy, and composition for radiation therapy
KR102195221B1 (en) 2019-12-31 2020-12-24 서울대학교산학협력단 Pharmaceutical composition for combination of radiotherapy for treating triple negative breast cancer comprising phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 inhibitor
WO2021231528A1 (en) * 2020-05-12 2021-11-18 Rush University Medical Center Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
CN103796680A (en) 2011-06-21 2014-05-14 约翰霍普金斯大学 Focused radiation for augmenting immune-based therapies against neoplasms
CN102935228B (en) 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 Reagent for tumor treatment, its use and method
EP3763741A1 (en) * 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
IN2014KN00920A (en) 2012-06-21 2015-10-09 Compugen Ltd
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
ES2660027T3 (en) * 2012-10-01 2018-03-20 Adaptive Biotechnologies Corporation Evaluation of immunocompetence by the diversity of adaptive immunity receptors and clonal characterization
US20150344577A1 (en) 2013-01-11 2015-12-03 Dingfu Biotarget Co., Ltd Agents for treating tumors, use and method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446401B2 (en) 2018-12-03 2022-09-20 Fusion Pharmaceuticals Inc. Actinium-225 and checkpoint inhibitor combination therapy

Also Published As

Publication number Publication date
JP2017525661A (en) 2017-09-07
KR20220082097A (en) 2022-06-16
EP4144412A1 (en) 2023-03-08
IL249133A0 (en) 2017-01-31
AU2020210207B2 (en) 2023-02-02
JP7258981B2 (en) 2023-04-17
EP3157629A1 (en) 2017-04-26
US20160051672A1 (en) 2016-02-25
EP3157629B1 (en) 2022-10-05
AU2023202654A1 (en) 2023-05-18
AU2020210207A1 (en) 2020-08-20
TWI751101B (en) 2022-01-01
PT3157629T (en) 2022-12-20
MX2021004828A (en) 2021-09-21
RU2017101312A (en) 2018-07-20
JP6877147B2 (en) 2021-05-26
TWI781021B (en) 2022-10-11
CA2950046A1 (en) 2015-12-23
SG10202108654PA (en) 2021-09-29
US10092645B2 (en) 2018-10-09
CA2950046C (en) 2023-02-14
KR20230113847A (en) 2023-08-01
TW202228777A (en) 2022-08-01
KR20170015460A (en) 2017-02-08
TW201617093A (en) 2016-05-16
RU2711408C2 (en) 2020-01-17
CN107073107A (en) 2017-08-18
PL3157629T3 (en) 2023-01-30
JP2020121978A (en) 2020-08-13
SG11201610600SA (en) 2017-01-27
KR102592781B1 (en) 2023-10-20
HUE060689T2 (en) 2023-04-28
ES2933603T3 (en) 2023-02-10
DK3157629T3 (en) 2022-12-19
MX2021004821A (en) 2021-08-19
IL249133B (en) 2022-04-01
AU2015276173B2 (en) 2020-08-20
RU2017101312A3 (en) 2019-01-29
WO2015193352A1 (en) 2015-12-23
JP2023093538A (en) 2023-07-04
MX2016015346A (en) 2017-08-10
AU2015276173A1 (en) 2016-12-22
BR112016028964A2 (en) 2017-10-17
JP2022031638A (en) 2022-02-22

Similar Documents

Publication Publication Date Title
US20190192655A1 (en) Methods of treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
US20230265200A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
TWI786044B (en) Methods of treating skin cancer by administering a pd-1 inhibitor
US20190382491A1 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and anti-cd137
JP2023554422A (en) Multispecific antibodies for cancer treatment
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
US20170100433A1 (en) Modified natural killer cells having anti-fugetactic properties and uses thereof
RU2771759C2 (en) Antibodies against pd-1 for treatment of lung cancer
KR20240162170A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
EA045900B1 (en) COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION FOR THE TREATMENT OF MALIGNANT TUMOR
EA040891B1 (en) METHODS FOR TREATMENT OR INHIBITION OF GROWTH OF SQUAT CELL SKIN CARCINOMA USING ANTIBODY AGAINST PD-1
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE UNIVERSITY OF MANCHESTER, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ILLIDGE, TIM;REEL/FRAME:046790/0393

Effective date: 20150515

Owner name: THE UNIVERSITY OF MANCHESTER, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOVEDI, SIMON;REEL/FRAME:046790/0168

Effective date: 20150515

Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEWART, ROSS A.;MORROW, MICHELLE;WILKINSON, ROBERT W.;AND OTHERS;SIGNING DATES FROM 20150324 TO 20150330;REEL/FRAME:046789/0940

Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE UNIVERSITY OF MANCHESTER;REEL/FRAME:047016/0556

Effective date: 20151014

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION